Aberman michael s - direct investment history in Regeneron pharmaceuticals inc

Filed on 2017-06-23 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001708138-17-000011.txt Sec File: edgar/data/1487767/0001708138-17-000011-index.htm

2017-06-21 Aberman Michael S (CIK 1487767) through Direct (Svp Strategy Investor Relation)

Invested in Regeneron Pharmaceuticals Inc sold 4500 shares at $0.0 remaining shares owned 3000

Non-Qualified Stock Option Right To Buy Regeneron Pharmaceuticals Inc Regn exercise price 30.63 has valueitem expiration due date 2020-12-14 underlying security shares 4500 underlying security title Common Stock

f1 disposition/acquisition made pursuant to a plan intended to comply with rule 10b5-1(c).
f8 the stock option award vests in four equal annual installments, commencing one year after the date of grant.


Filed on 2017-06-23 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001708138-17-000011.txt Sec File: edgar/data/1487767/0001708138-17-000011-index.htm

2017-06-22 Aberman Michael S (CIK 1487767) through Direct (Svp Strategy Investor Relation)

Invested in Regeneron Pharmaceuticals Inc sold 100 shares at $541.0 remaining shares owned 4693

Common Stock Regeneron Pharmaceuticals Inc Regn Transaction code: S Open market or private sale of securities

f1 disposition/acquisition made pursuant to a plan intended to comply with rule 10b5-1(c).


Filed on 2017-06-23 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001708138-17-000011.txt Sec File: edgar/data/1487767/0001708138-17-000011-index.htm

2017-06-22 Aberman Michael S (CIK 1487767) through Direct (Svp Strategy Investor Relation)

Invested in Regeneron Pharmaceuticals Inc sold 100 shares at $538.3 remaining shares owned 4793

Common Stock Regeneron Pharmaceuticals Inc Regn Transaction code: S Open market or private sale of securities

f1 disposition/acquisition made pursuant to a plan intended to comply with rule 10b5-1(c).


Filed on 2017-06-23 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001708138-17-000011.txt Sec File: edgar/data/1487767/0001708138-17-000011-index.htm

2017-06-22 Aberman Michael S (CIK 1487767) through Direct (Svp Strategy Investor Relation)

Invested in Regeneron Pharmaceuticals Inc sold 100 shares at $537.5 remaining shares owned 4893

Common Stock Regeneron Pharmaceuticals Inc Regn Transaction code: S Open market or private sale of securities

f1 disposition/acquisition made pursuant to a plan intended to comply with rule 10b5-1(c).


Filed on 2017-06-23 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001708138-17-000011.txt Sec File: edgar/data/1487767/0001708138-17-000011-index.htm

2017-06-22 Aberman Michael S (CIK 1487767) through Direct (Svp Strategy Investor Relation)

Invested in Regeneron Pharmaceuticals Inc sold 400 shares at $536.52 remaining shares owned 4993

Common Stock Regeneron Pharmaceuticals Inc Regn Transaction code: S Open market or private sale of securities

f1 disposition/acquisition made pursuant to a plan intended to comply with rule 10b5-1(c).
f7 represents volume-weighted average price of sales of 400 shares of company stock on june 22, 2017 at prices ranging from $536.15 to $536.93. upon request by the commission staff, the company, or a security holder of the company, the reporting person will provide full information regarding the number of shares sold by the reporting person on june 22, 2017 at each separate price.


Filed on 2017-06-23 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001708138-17-000011.txt Sec File: edgar/data/1487767/0001708138-17-000011-index.htm

2017-06-22 Aberman Michael S (CIK 1487767) through Direct (Svp Strategy Investor Relation)

Invested in Regeneron Pharmaceuticals Inc sold 200 shares at $534.51 remaining shares owned 5393

Common Stock Regeneron Pharmaceuticals Inc Regn Transaction code: S Open market or private sale of securities

f1 disposition/acquisition made pursuant to a plan intended to comply with rule 10b5-1(c).
f6 represents volume-weighted average price of sales of 200 shares of company stock on june 22, 2017 at prices ranging from $534.16 to $534.85. upon request by the commission staff, the company, or a security holder of the company, the reporting person will provide full information regarding the number of shares sold by the reporting person on june 22, 2017 at each separate price.


Filed on 2017-06-23 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001708138-17-000011.txt Sec File: edgar/data/1487767/0001708138-17-000011-index.htm

2017-06-22 Aberman Michael S (CIK 1487767) through Direct (Svp Strategy Investor Relation)

Invested in Regeneron Pharmaceuticals Inc sold 200 shares at $533.48 remaining shares owned 5593

Common Stock Regeneron Pharmaceuticals Inc Regn Transaction code: S Open market or private sale of securities

f1 disposition/acquisition made pursuant to a plan intended to comply with rule 10b5-1(c).
f5 represents volume-weighted average price of sales of 200 shares of company stock on june 22, 2017 at prices ranging from $533.17 to $533.78. upon request by the commission staff, the company, or a security holder of the company, the reporting person will provide full information regarding the number of shares sold by the reporting person on june 22, 2017 at each separate price.


Filed on 2017-06-23 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001708138-17-000011.txt Sec File: edgar/data/1487767/0001708138-17-000011-index.htm

2017-06-22 Aberman Michael S (CIK 1487767) through Direct (Svp Strategy Investor Relation)

Invested in Regeneron Pharmaceuticals Inc sold 200 shares at $532.27 remaining shares owned 5793

Common Stock Regeneron Pharmaceuticals Inc Regn Transaction code: S Open market or private sale of securities

f1 disposition/acquisition made pursuant to a plan intended to comply with rule 10b5-1(c).
f4 represents volume-weighted average price of sales of 200 shares of company stock on june 22, 2017 at prices ranging from $532.18 to $532.35. upon request by the commission staff, the company, or a security holder of the company, the reporting person will provide full information regarding the number of shares sold by the reporting person on june 22, 2017 at each separate price.


Filed on 2017-06-23 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001708138-17-000011.txt Sec File: edgar/data/1487767/0001708138-17-000011-index.htm

2017-06-22 Aberman Michael S (CIK 1487767) through Direct (Svp Strategy Investor Relation)

Invested in Regeneron Pharmaceuticals Inc sold 274 shares at $531.51 remaining shares owned 5993

Common Stock Regeneron Pharmaceuticals Inc Regn Transaction code: S Open market or private sale of securities

f1 disposition/acquisition made pursuant to a plan intended to comply with rule 10b5-1(c).
f3 represents volume-weighted average price of sales of 274 shares of company stock on june 22, 2017 at prices ranging from $531.05 to $531.85. upon request by the commission staff, the company, or a security holder of the company, the reporting person will provide full information regarding the number of shares sold by the reporting person on june 22, 2017 at each separate price.


Filed on 2017-06-23 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001708138-17-000011.txt Sec File: edgar/data/1487767/0001708138-17-000011-index.htm

2017-06-22 Aberman Michael S (CIK 1487767) through Direct (Svp Strategy Investor Relation)

Invested in Regeneron Pharmaceuticals Inc sold 100 shares at $530.66 remaining shares owned 6267

Common Stock Regeneron Pharmaceuticals Inc Regn Transaction code: S Open market or private sale of securities

f1 disposition/acquisition made pursuant to a plan intended to comply with rule 10b5-1(c).


Filed on 2017-06-23 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001708138-17-000011.txt Sec File: edgar/data/1487767/0001708138-17-000011-index.htm

2017-06-22 Aberman Michael S (CIK 1487767) through Direct (Svp Strategy Investor Relation)

Invested in Regeneron Pharmaceuticals Inc sold 100 shares at $529.61 remaining shares owned 6367

Common Stock Regeneron Pharmaceuticals Inc Regn Transaction code: S Open market or private sale of securities

f1 disposition/acquisition made pursuant to a plan intended to comply with rule 10b5-1(c).


Filed on 2017-06-23 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001708138-17-000011.txt Sec File: edgar/data/1487767/0001708138-17-000011-index.htm

2017-06-22 Aberman Michael S (CIK 1487767) through Direct (Svp Strategy Investor Relation)

Invested in Regeneron Pharmaceuticals Inc sold 100 shares at $526.02 remaining shares owned 6467

Common Stock Regeneron Pharmaceuticals Inc Regn Transaction code: S Open market or private sale of securities

f1 disposition/acquisition made pursuant to a plan intended to comply with rule 10b5-1(c).


Filed on 2017-06-23 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001708138-17-000011.txt Sec File: edgar/data/1487767/0001708138-17-000011-index.htm

2017-06-22 Aberman Michael S (CIK 1487767) through Direct (Svp Strategy Investor Relation)

Invested in Regeneron Pharmaceuticals Inc sold 395 shares at $525.21 remaining shares owned 6567

Common Stock Regeneron Pharmaceuticals Inc Regn Transaction code: S Open market or private sale of securities

f1 disposition/acquisition made pursuant to a plan intended to comply with rule 10b5-1(c).
f2 represents volume-weighted average price of sales of 395 shares of company stock on june 22, 2017 at prices ranging from $525.00 to $525.83. upon request by the commission staff, the company, or a security holder of the company, the reporting person will provide full information regarding the number of shares sold by the reporting person on june 22, 2017 at each separate price.


Filed on 2017-06-23 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001708138-17-000011.txt Sec File: edgar/data/1487767/0001708138-17-000011-index.htm

2017-06-21 Aberman Michael S (CIK 1487767) through Direct (Svp Strategy Investor Relation)

Invested in Regeneron Pharmaceuticals Inc sold 1961 shares at $510.02 remaining shares owned 6962

Common Stock Regeneron Pharmaceuticals Inc Regn Transaction code: F Payment of exercise price or tax liability by delivering or withholding securities

f1 disposition/acquisition made pursuant to a plan intended to comply with rule 10b5-1(c).


Filed on 2017-06-23 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001708138-17-000011.txt Sec File: edgar/data/1487767/0001708138-17-000011-index.htm

2017-06-21 Aberman Michael S (CIK 1487767) through Direct (Svp Strategy Investor Relation)

Invested in Regeneron Pharmaceuticals Inc sold 270 shares at $510.02 remaining shares owned 8923

Common Stock Regeneron Pharmaceuticals Inc Regn Transaction code: F Payment of exercise price or tax liability by delivering or withholding securities

f1 disposition/acquisition made pursuant to a plan intended to comply with rule 10b5-1(c).


Filed on 2017-06-23 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001708138-17-000011.txt Sec File: edgar/data/1487767/0001708138-17-000011-index.htm

2017-06-21 Aberman Michael S (CIK 1487767) through Direct (Svp Strategy Investor Relation)

Invested in Regeneron Pharmaceuticals Inc bought 4500 shares at $30.63 remaining shares owned 9193

Common Stock Regeneron Pharmaceuticals Inc Regn Transaction code: M Exercise or conversion of derivative security

f1 disposition/acquisition made pursuant to a plan intended to comply with rule 10b5-1(c).


Filed on 2017-06-23 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001708138-17-000011.txt Sec File: edgar/data/1487767/0001708138-17-000011-index.htm

2017-06-21 Aberman Michael S (CIK 1487767) through Direct (Svp Strategy Investor Relation)

Invested in Regeneron Pharmaceuticals Inc remaining shares owned 448

Common Stock Regeneron Pharmaceuticals Inc Regn


Filed on 2017-06-23 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001708138-17-000011.txt Sec File: edgar/data/1487767/0001708138-17-000011-index.htm

2017-06-21 Aberman Michael S (CIK 1487767) through Direct (Svp Strategy Investor Relation)

Invested in Regeneron Pharmaceuticals Inc remaining shares owned 11805

Common Stock Regeneron Pharmaceuticals Inc Regn


Filed on 2016-12-19 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-16-000092.txt Sec File: edgar/data/1487767/0001237899-16-000092-index.htm

2016-12-16 Aberman Michael S (CIK 1487767) through Direct (Svp Strategy Investor Relation)

Invested in Regeneron Pharmaceuticals Inc bought 21675 shares at $0.0 remaining shares owned 21675

Non-Qualified Stock Option Right To Buy Regeneron Pharmaceuticals Inc Regn exercise price 381.92 has valueitem expiration due date 2026-12-16 underlying security shares 21675 underlying security title Common Stock

f1 the stock option award vests in four equal annual installments, commencing one year after the date of grant.


Filed on 2015-12-18 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-15-000067.txt Sec File: edgar/data/1487767/0001237899-15-000067-index.htm

2015-12-16 Aberman Michael S (CIK 1487767) through Direct (Svp Strategy Investor Relation)

Invested in Regeneron Pharmaceuticals Inc bought 25500.0 shares at $0.0 remaining shares owned 25500

Non-Qualified Stock Option Right To Buy Regeneron Pharmaceuticals Inc Regn exercise price 555.67 has valueitem expiration due date 2025-12-16 underlying security shares 25500 underlying security title Common Stock

f2 the stock option award vests in four equal annual installments, commencing one year after the date of grant.


Filed on 2015-12-18 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-15-000067.txt Sec File: edgar/data/1487767/0001237899-15-000067-index.htm

2015-12-17 Aberman Michael S (CIK 1487767) through Direct (Svp Strategy Investor Relation)

Invested in Regeneron Pharmaceuticals Inc sold 4000.0 shares at $0.0 remaining shares owned 166

Incentive Stock Option Right To Buy Regeneron Pharmaceuticals Inc Regn exercise price 24.0 has valueitem expiration due date 2020-03-22 underlying security shares 4000 underlying security title Common Stock

f1 the stock option award (combined incentive stock option and non-qualified stock option) vests over five years, commencing one year after the date of grant. 12,500 options vest on the first anniversary, 25,000 options vest on the second anniversary, 25,000 options vest on the third anniversary, 25,000 options vest on the fourth anniversary, and 12,500 options vest on the fifth anniversary of the date of grant.


Filed on 2015-12-18 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-15-000067.txt Sec File: edgar/data/1487767/0001237899-15-000067-index.htm

2015-12-17 Aberman Michael S (CIK 1487767) through Direct (Svp Strategy Investor Relation)

Invested in Regeneron Pharmaceuticals Inc bought 4000 shares at $24.0 remaining shares owned 16498

Common Stock Regeneron Pharmaceuticals Inc Regn Transaction code: M Exercise or conversion of derivative security


Filed on 2015-12-18 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-15-000067.txt Sec File: edgar/data/1487767/0001237899-15-000067-index.htm

2015-12-16 Aberman Michael S (CIK 1487767) through Direct (Svp Strategy Investor Relation)

Invested in Regeneron Pharmaceuticals Inc remaining shares owned 407

Common Stock Regeneron Pharmaceuticals Inc Regn


Filed on 2015-03-25 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-15-000027.txt Sec File: edgar/data/1487767/0001237899-15-000027-index.htm

2015-03-24 Aberman Michael S (CIK 1487767) through Direct (Svp Strategy Investor Relation)

Invested in Regeneron Pharmaceuticals Inc sold 100 shares at $482.56 remaining shares owned 12498

Common Stock Regeneron Pharmaceuticals Inc Regn Transaction code: S Open market or private sale of securities

f1 disposition/acquisition made pursuant to a plan intended to comply with rule 10b5-1(c).


Filed on 2015-03-25 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-15-000027.txt Sec File: edgar/data/1487767/0001237899-15-000027-index.htm

2015-03-24 Aberman Michael S (CIK 1487767) through Direct (Svp Strategy Investor Relation)

Invested in Regeneron Pharmaceuticals Inc sold 1100 shares at $481.59 remaining shares owned 12598

Common Stock Regeneron Pharmaceuticals Inc Regn Transaction code: S Open market or private sale of securities

f1 disposition/acquisition made pursuant to a plan intended to comply with rule 10b5-1(c).
f9 represents volume-weighted average price of sales of 1,100 shares of company stock on march 24, 2015 at prices ranging from $481.03 to $481.92. upon request by the commission staff, the company, or a security holder of the company, the reporting person will provide full information regarding the number of shares sold by the reporting person on march 24, 2015 at each separate price.


Filed on 2015-03-25 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-15-000027.txt Sec File: edgar/data/1487767/0001237899-15-000027-index.htm

2015-03-24 Aberman Michael S (CIK 1487767) through Direct (Svp Strategy Investor Relation)

Invested in Regeneron Pharmaceuticals Inc sold 800 shares at $480.7 remaining shares owned 13698

Common Stock Regeneron Pharmaceuticals Inc Regn Transaction code: S Open market or private sale of securities

f1 disposition/acquisition made pursuant to a plan intended to comply with rule 10b5-1(c).
f8 represents volume-weighted average price of sales of 800 shares of company stock on march 24, 2015 at prices ranging from $480.12 to $480.95. upon request by the commission staff, the company, or a security holder of the company, the reporting person will provide full information regarding the number of shares sold by the reporting person on march 24, 2015 at each separate price.


Filed on 2015-03-25 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-15-000027.txt Sec File: edgar/data/1487767/0001237899-15-000027-index.htm

2015-03-24 Aberman Michael S (CIK 1487767) through Direct (Svp Strategy Investor Relation)

Invested in Regeneron Pharmaceuticals Inc sold 500 shares at $479.39 remaining shares owned 14498

Common Stock Regeneron Pharmaceuticals Inc Regn Transaction code: S Open market or private sale of securities

f1 disposition/acquisition made pursuant to a plan intended to comply with rule 10b5-1(c).
f7 represents volume-weighted average price of sales of 500 shares of company stock on march 24, 2015 at prices ranging from $479.09 to $479.60. upon request by the commission staff, the company, or a security holder of the company, the reporting person will provide full information regarding the number of shares sold by the reporting person on march 24, 2015 at each separate price.


Filed on 2015-03-25 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-15-000027.txt Sec File: edgar/data/1487767/0001237899-15-000027-index.htm

2015-03-24 Aberman Michael S (CIK 1487767) through Direct (Svp Strategy Investor Relation)

Invested in Regeneron Pharmaceuticals Inc sold 530 shares at $478.46 remaining shares owned 14998

Common Stock Regeneron Pharmaceuticals Inc Regn Transaction code: S Open market or private sale of securities

f1 disposition/acquisition made pursuant to a plan intended to comply with rule 10b5-1(c).
f6 represents volume-weighted average price of sales of 530 shares of company stock on march 24, 2015 at prices ranging from $478.03 to $478.83. upon request by the commission staff, the company, or a security holder of the company, the reporting person will provide full information regarding the number of shares sold by the reporting person on march 24, 2015 at each separate price.


Filed on 2015-03-25 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-15-000027.txt Sec File: edgar/data/1487767/0001237899-15-000027-index.htm

2015-03-24 Aberman Michael S (CIK 1487767) through Direct (Svp Strategy Investor Relation)

Invested in Regeneron Pharmaceuticals Inc sold 573 shares at $477.59 remaining shares owned 15528

Common Stock Regeneron Pharmaceuticals Inc Regn Transaction code: S Open market or private sale of securities

f1 disposition/acquisition made pursuant to a plan intended to comply with rule 10b5-1(c).
f5 represents volume-weighted average price of sales of 573 shares of company stock on march 24, 2015 at prices ranging from $477.11 to $477.94. upon request by the commission staff, the company, or a security holder of the company, the reporting person will provide full information regarding the number of shares sold by the reporting person on march 24, 2015 at each separate price.


Filed on 2015-03-25 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-15-000027.txt Sec File: edgar/data/1487767/0001237899-15-000027-index.htm

2015-03-24 Aberman Michael S (CIK 1487767) through Direct (Svp Strategy Investor Relation)

Invested in Regeneron Pharmaceuticals Inc sold 740 shares at $476.53 remaining shares owned 16101

Common Stock Regeneron Pharmaceuticals Inc Regn Transaction code: S Open market or private sale of securities

f1 disposition/acquisition made pursuant to a plan intended to comply with rule 10b5-1(c).
f4 represents volume-weighted average price of sales of 740 shares of company stock on march 24, 2015 at prices ranging from $476.21 to $476.79. upon request by the commission staff, the company, or a security holder of the company, the reporting person will provide full information regarding the number of shares sold by the reporting person on march 24, 2015 at each separate price.


Filed on 2015-03-25 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-15-000027.txt Sec File: edgar/data/1487767/0001237899-15-000027-index.htm

2015-03-24 Aberman Michael S (CIK 1487767) through Direct (Svp Strategy Investor Relation)

Invested in Regeneron Pharmaceuticals Inc sold 200 shares at $475.83 remaining shares owned 16841

Common Stock Regeneron Pharmaceuticals Inc Regn Transaction code: S Open market or private sale of securities

f1 disposition/acquisition made pursuant to a plan intended to comply with rule 10b5-1(c).
f3 represents volume-weighted average price of sales of 200 shares of company stock on march 24, 2015 at prices ranging from $475.79 to $475.86. upon request by the commission staff, the company, or a security holder of the company, the reporting person will provide full information regarding the number of shares sold by the reporting person on march 24, 2015 at each separate price.


Filed on 2015-03-25 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-15-000027.txt Sec File: edgar/data/1487767/0001237899-15-000027-index.htm

2015-03-24 Aberman Michael S (CIK 1487767) through Direct (Svp Strategy Investor Relation)

Invested in Regeneron Pharmaceuticals Inc sold 300 shares at $474.79 remaining shares owned 17041

Common Stock Regeneron Pharmaceuticals Inc Regn Transaction code: S Open market or private sale of securities

f1 disposition/acquisition made pursuant to a plan intended to comply with rule 10b5-1(c).
f2 represents volume-weighted average price of sales of 300 shares of company stock on march 24, 2015 at prices ranging from $474.50 to $474.99. upon request by the commission staff, the company, or a security holder of the company, the reporting person will provide full information regarding the number of shares sold by the reporting person on march 24, 2015 at each separate price.


Filed on 2015-03-25 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-15-000027.txt Sec File: edgar/data/1487767/0001237899-15-000027-index.htm

2015-03-23 Aberman Michael S (CIK 1487767) through Direct (Svp Strategy Investor Relation)

Invested in Regeneron Pharmaceuticals Inc sold 5157 shares at $476.5 remaining shares owned 17341

Common Stock Regeneron Pharmaceuticals Inc Regn Transaction code: F Payment of exercise price or tax liability by delivering or withholding securities

f1 disposition/acquisition made pursuant to a plan intended to comply with rule 10b5-1(c).


Filed on 2015-03-25 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-15-000027.txt Sec File: edgar/data/1487767/0001237899-15-000027-index.htm

2015-03-23 Aberman Michael S (CIK 1487767) through Direct (Svp Strategy Investor Relation)

Invested in Regeneron Pharmaceuticals Inc remaining shares owned 407

Common Stock Regeneron Pharmaceuticals Inc Regn


Filed on 2015-03-19 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-15-000026.txt Sec File: edgar/data/1487767/0001237899-15-000026-index.htm

2015-03-17 Aberman Michael S (CIK 1487767) through Direct (Svp Strategy Investor Relation)

Invested in Regeneron Pharmaceuticals Inc sold 7500.0 shares at $0.0 remaining shares owned 14168

Non-Qualified Stock Option Right To Buy Regeneron Pharmaceuticals Inc Regn exercise price 24.0 has valueitem expiration due date 2020-03-22 underlying security shares 7500 underlying security title Common Stock

f1 disposition/acquisition made pursuant to a plan intended to comply with rule 10b5-1(c).
f6 the stock option award (combined incentive stock option and non-qualified stock option) vests over five years, commencing one year after the date of grant. 12,500 options vest on the first anniversary, 25,000 options vest on the second anniversary, 25,000 options vest on the third anniversary, 25,000 options vest on the fourth anniversary, and 12,500 options vest on the fifth anniversary of the date of grant.


Filed on 2015-03-19 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-15-000026.txt Sec File: edgar/data/1487767/0001237899-15-000026-index.htm

2015-03-17 Aberman Michael S (CIK 1487767) through Direct (Svp Strategy Investor Relation)

Invested in Regeneron Pharmaceuticals Inc sold 3898.0 shares at $0.0 remaining shares owned 4166

Incentive Stock Option Right To Buy Regeneron Pharmaceuticals Inc Regn exercise price 24.0 has valueitem expiration due date 2020-03-22 underlying security shares 3898 underlying security title Common Stock

f6 the stock option award (combined incentive stock option and non-qualified stock option) vests over five years, commencing one year after the date of grant. 12,500 options vest on the first anniversary, 25,000 options vest on the second anniversary, 25,000 options vest on the third anniversary, 25,000 options vest on the fourth anniversary, and 12,500 options vest on the fifth anniversary of the date of grant.


Filed on 2015-03-19 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-15-000026.txt Sec File: edgar/data/1487767/0001237899-15-000026-index.htm

2015-03-18 Aberman Michael S (CIK 1487767) through Direct (Svp Strategy Investor Relation)

Invested in Regeneron Pharmaceuticals Inc sold 100 shares at $472.14 remaining shares owned 22498

Common Stock Regeneron Pharmaceuticals Inc Regn Transaction code: S Open market or private sale of securities

f1 disposition/acquisition made pursuant to a plan intended to comply with rule 10b5-1(c).


Filed on 2015-03-19 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-15-000026.txt Sec File: edgar/data/1487767/0001237899-15-000026-index.htm

2015-03-18 Aberman Michael S (CIK 1487767) through Direct (Svp Strategy Investor Relation)

Invested in Regeneron Pharmaceuticals Inc sold 100 shares at $471.24 remaining shares owned 22598

Common Stock Regeneron Pharmaceuticals Inc Regn Transaction code: S Open market or private sale of securities

f1 disposition/acquisition made pursuant to a plan intended to comply with rule 10b5-1(c).


Filed on 2015-03-19 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-15-000026.txt Sec File: edgar/data/1487767/0001237899-15-000026-index.htm

2015-03-18 Aberman Michael S (CIK 1487767) through Direct (Svp Strategy Investor Relation)

Invested in Regeneron Pharmaceuticals Inc sold 142 shares at $470.97 remaining shares owned 22698

Common Stock Regeneron Pharmaceuticals Inc Regn Transaction code: S Open market or private sale of securities

f1 disposition/acquisition made pursuant to a plan intended to comply with rule 10b5-1(c).


Filed on 2015-03-19 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-15-000026.txt Sec File: edgar/data/1487767/0001237899-15-000026-index.htm

2015-03-18 Aberman Michael S (CIK 1487767) through Direct (Svp Strategy Investor Relation)

Invested in Regeneron Pharmaceuticals Inc sold 100 shares at $469.68 remaining shares owned 22840

Common Stock Regeneron Pharmaceuticals Inc Regn Transaction code: S Open market or private sale of securities

f1 disposition/acquisition made pursuant to a plan intended to comply with rule 10b5-1(c).


Filed on 2015-03-19 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-15-000026.txt Sec File: edgar/data/1487767/0001237899-15-000026-index.htm

2015-03-18 Aberman Michael S (CIK 1487767) through Direct (Svp Strategy Investor Relation)

Invested in Regeneron Pharmaceuticals Inc sold 100 shares at $468.92 remaining shares owned 22940

Common Stock Regeneron Pharmaceuticals Inc Regn Transaction code: S Open market or private sale of securities

f1 disposition/acquisition made pursuant to a plan intended to comply with rule 10b5-1(c).


Filed on 2015-03-19 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-15-000026.txt Sec File: edgar/data/1487767/0001237899-15-000026-index.htm

2015-03-18 Aberman Michael S (CIK 1487767) through Direct (Svp Strategy Investor Relation)

Invested in Regeneron Pharmaceuticals Inc sold 500 shares at $465.42 remaining shares owned 23040

Common Stock Regeneron Pharmaceuticals Inc Regn Transaction code: S Open market or private sale of securities

f1 disposition/acquisition made pursuant to a plan intended to comply with rule 10b5-1(c).
f5 represents volume-weighted average price of sales of 500 shares of company stock on march 18, 2015 at prices ranging from $465.02 to $465.75. upon request by the commission staff, the company, or a security holder of the company, the reporting person will provide full information regarding the number of shares sold by the reporting person on march 18, 2015 at each separate price.


Filed on 2015-03-19 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-15-000026.txt Sec File: edgar/data/1487767/0001237899-15-000026-index.htm

2015-03-18 Aberman Michael S (CIK 1487767) through Direct (Svp Strategy Investor Relation)

Invested in Regeneron Pharmaceuticals Inc sold 500 shares at $464.44 remaining shares owned 23540

Common Stock Regeneron Pharmaceuticals Inc Regn Transaction code: S Open market or private sale of securities

f1 disposition/acquisition made pursuant to a plan intended to comply with rule 10b5-1(c).
f4 represents volume-weighted average price of sales of 500 shares of company stock on march 18, 2015 at prices ranging from $464.11 to $464.95. upon request by the commission staff, the company, or a security holder of the company, the reporting person will provide full information regarding the number of shares sold by the reporting person on march 18, 2015 at each separate price.


Filed on 2015-03-19 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-15-000026.txt Sec File: edgar/data/1487767/0001237899-15-000026-index.htm

2015-03-18 Aberman Michael S (CIK 1487767) through Direct (Svp Strategy Investor Relation)

Invested in Regeneron Pharmaceuticals Inc sold 1500 shares at $463.6 remaining shares owned 24040

Common Stock Regeneron Pharmaceuticals Inc Regn Transaction code: S Open market or private sale of securities

f1 disposition/acquisition made pursuant to a plan intended to comply with rule 10b5-1(c).
f3 represents volume-weighted average price of sales of 1,500 shares of company stock on march 18, 2015 at prices ranging from $463.24 to $463.96. upon request by the commission staff, the company, or a security holder of the company, the reporting person will provide full information regarding the number of shares sold by the reporting person on march 18, 2015 at each separate price.


Filed on 2015-03-19 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-15-000026.txt Sec File: edgar/data/1487767/0001237899-15-000026-index.htm

2015-03-18 Aberman Michael S (CIK 1487767) through Direct (Svp Strategy Investor Relation)

Invested in Regeneron Pharmaceuticals Inc sold 400 shares at $462.84 remaining shares owned 25540

Common Stock Regeneron Pharmaceuticals Inc Regn Transaction code: S Open market or private sale of securities

f1 disposition/acquisition made pursuant to a plan intended to comply with rule 10b5-1(c).
f2 represents volume-weighted average price of sales of 400 shares of company stock on march 18, 2015 at prices ranging from $462.69 to $462.97. upon request by the commission staff, the company, or a security holder of the company, the reporting person will provide full information regarding the number of shares sold by the reporting person on march 18, 2015 at each separate price.


Filed on 2015-03-19 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-15-000026.txt Sec File: edgar/data/1487767/0001237899-15-000026-index.htm

2015-03-17 Aberman Michael S (CIK 1487767) through Direct (Svp Strategy Investor Relation)

Invested in Regeneron Pharmaceuticals Inc sold 3665 shares at $457.91 remaining shares owned 25940

Common Stock Regeneron Pharmaceuticals Inc Regn Transaction code: F Payment of exercise price or tax liability by delivering or withholding securities

f1 disposition/acquisition made pursuant to a plan intended to comply with rule 10b5-1(c).


Filed on 2015-03-19 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-15-000026.txt Sec File: edgar/data/1487767/0001237899-15-000026-index.htm

2015-03-17 Aberman Michael S (CIK 1487767) through Direct (Svp Strategy Investor Relation)

Invested in Regeneron Pharmaceuticals Inc sold 393 shares at $457.91 remaining shares owned 29605

Common Stock Regeneron Pharmaceuticals Inc Regn Transaction code: F Payment of exercise price or tax liability by delivering or withholding securities

f1 disposition/acquisition made pursuant to a plan intended to comply with rule 10b5-1(c).


Filed on 2015-03-19 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-15-000026.txt Sec File: edgar/data/1487767/0001237899-15-000026-index.htm

2015-03-17 Aberman Michael S (CIK 1487767) through Direct (Svp Strategy Investor Relation)

Invested in Regeneron Pharmaceuticals Inc bought 7500 shares at $24.0 remaining shares owned 29998

Common Stock Regeneron Pharmaceuticals Inc Regn Transaction code: M Exercise or conversion of derivative security

f1 disposition/acquisition made pursuant to a plan intended to comply with rule 10b5-1(c).


Filed on 2015-03-19 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-15-000026.txt Sec File: edgar/data/1487767/0001237899-15-000026-index.htm

2015-03-17 Aberman Michael S (CIK 1487767) through Direct (Svp Strategy Investor Relation)

Invested in Regeneron Pharmaceuticals Inc bought 3898 shares at $24.0 remaining shares owned 22498

Common Stock Regeneron Pharmaceuticals Inc Regn Transaction code: M Exercise or conversion of derivative security


Filed on 2015-03-19 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-15-000026.txt Sec File: edgar/data/1487767/0001237899-15-000026-index.htm

2015-03-17 Aberman Michael S (CIK 1487767) through Direct (Svp Strategy Investor Relation)

Invested in Regeneron Pharmaceuticals Inc remaining shares owned 407

Common Stock Regeneron Pharmaceuticals Inc Regn


Filed on 2015-02-25 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-15-000021.txt Sec File: edgar/data/1487767/0001237899-15-000021-index.htm

2015-02-23 Aberman Michael S (CIK 1487767) through Direct (Svp Strategy Investor Relation)

Invested in Regeneron Pharmaceuticals Inc sold 7500.0 shares at $0.0 remaining shares owned 7500

Non-Qualified Stock Option Right To Buy Regeneron Pharmaceuticals Inc Regn exercise price 30.63 has valueitem expiration due date 2020-12-14 underlying security shares 7500 underlying security title Common Stock

f1 disposition/acquisition made pursuant to a plan intended to comply with rule 10b5-1(c).
f7 the stock option award vests in four equal annual installments, commencing one year after the date of grant.


Filed on 2015-02-25 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-15-000021.txt Sec File: edgar/data/1487767/0001237899-15-000021-index.htm

2015-02-24 Aberman Michael S (CIK 1487767) through Direct (Svp Strategy Investor Relation)

Invested in Regeneron Pharmaceuticals Inc sold 400 shares at $420.64 remaining shares owned 18600

Common Stock Regeneron Pharmaceuticals Inc Regn Transaction code: S Open market or private sale of securities

f1 disposition/acquisition made pursuant to a plan intended to comply with rule 10b5-1(c).
f6 represents volume-weighted average price of sales of 400 shares of company stock on february 24, 2015 at prices ranging from $420.30 to $420.97. upon request by the commission staff, the company, or a security holder of the company, the reporting person will provide full information regarding the number of shares sold by the reporting person on february 24, 2015 at each separate price.


Filed on 2015-02-25 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-15-000021.txt Sec File: edgar/data/1487767/0001237899-15-000021-index.htm

2015-02-24 Aberman Michael S (CIK 1487767) through Direct (Svp Strategy Investor Relation)

Invested in Regeneron Pharmaceuticals Inc sold 1103 shares at $419.52 remaining shares owned 19000

Common Stock Regeneron Pharmaceuticals Inc Regn Transaction code: S Open market or private sale of securities

f1 disposition/acquisition made pursuant to a plan intended to comply with rule 10b5-1(c).
f5 represents volume-weighted average price of sales of 1,103 shares of company stock on february 24, 2015 at prices ranging from $419.00 to $419.96. upon request by the commission staff, the company, or a security holder of the company, the reporting person will provide full information regarding the number of shares sold by the reporting person on february 24, 2015 at each separate price.


Filed on 2015-02-25 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-15-000021.txt Sec File: edgar/data/1487767/0001237899-15-000021-index.htm

2015-02-24 Aberman Michael S (CIK 1487767) through Direct (Svp Strategy Investor Relation)

Invested in Regeneron Pharmaceuticals Inc sold 800 shares at $418.33 remaining shares owned 20103

Common Stock Regeneron Pharmaceuticals Inc Regn Transaction code: S Open market or private sale of securities

f1 disposition/acquisition made pursuant to a plan intended to comply with rule 10b5-1(c).
f4 represents volume-weighted average price of sales of 800 shares of company stock on february 24, 2015 at prices ranging from $418.07 to $418.82. upon request by the commission staff, the company, or a security holder of the company, the reporting person will provide full information regarding the number of shares sold by the reporting person on february 24, 2015 at each separate price.


Filed on 2015-02-25 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-15-000021.txt Sec File: edgar/data/1487767/0001237899-15-000021-index.htm

2015-02-24 Aberman Michael S (CIK 1487767) through Direct (Svp Strategy Investor Relation)

Invested in Regeneron Pharmaceuticals Inc sold 471 shares at $417.23 remaining shares owned 20903

Common Stock Regeneron Pharmaceuticals Inc Regn Transaction code: S Open market or private sale of securities

f1 disposition/acquisition made pursuant to a plan intended to comply with rule 10b5-1(c).
f3 represents volume-weighted average price of sales of 471 shares of company stock on february 24, 2015 at prices ranging from $417.08 to $417.54. upon request by the commission staff, the company, or a security holder of the company, the reporting person will provide full information regarding the number of shares sold by the reporting person on february 24, 2015 at each separate price.


Filed on 2015-02-25 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-15-000021.txt Sec File: edgar/data/1487767/0001237899-15-000021-index.htm

2015-02-24 Aberman Michael S (CIK 1487767) through Direct (Svp Strategy Investor Relation)

Invested in Regeneron Pharmaceuticals Inc sold 600 shares at $416.31 remaining shares owned 21374

Common Stock Regeneron Pharmaceuticals Inc Regn Transaction code: S Open market or private sale of securities

f1 disposition/acquisition made pursuant to a plan intended to comply with rule 10b5-1(c).
f2 represents volume-weighted average price of sales of 600 shares of company stock on february 24, 2015 at prices ranging from $416.01 to $416.83. upon request by the commission staff, the company, or a security holder of the company, the reporting person will provide full information regarding the number of shares sold by the reporting person on february 24, 2015 at each separate price.


Filed on 2015-02-25 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-15-000021.txt Sec File: edgar/data/1487767/0001237899-15-000021-index.htm

2015-02-23 Aberman Michael S (CIK 1487767) through Direct (Svp Strategy Investor Relation)

Invested in Regeneron Pharmaceuticals Inc sold 3590 shares at $427.94 remaining shares owned 21974

Common Stock Regeneron Pharmaceuticals Inc Regn Transaction code: F Payment of exercise price or tax liability by delivering or withholding securities

f1 disposition/acquisition made pursuant to a plan intended to comply with rule 10b5-1(c).


Filed on 2015-02-25 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-15-000021.txt Sec File: edgar/data/1487767/0001237899-15-000021-index.htm

2015-02-23 Aberman Michael S (CIK 1487767) through Direct (Svp Strategy Investor Relation)

Invested in Regeneron Pharmaceuticals Inc sold 536 shares at $427.94 remaining shares owned 25564

Common Stock Regeneron Pharmaceuticals Inc Regn Transaction code: F Payment of exercise price or tax liability by delivering or withholding securities

f1 disposition/acquisition made pursuant to a plan intended to comply with rule 10b5-1(c).


Filed on 2015-02-25 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-15-000021.txt Sec File: edgar/data/1487767/0001237899-15-000021-index.htm

2015-02-23 Aberman Michael S (CIK 1487767) through Direct (Svp Strategy Investor Relation)

Invested in Regeneron Pharmaceuticals Inc bought 7500 shares at $30.63 remaining shares owned 26100

Common Stock Regeneron Pharmaceuticals Inc Regn Transaction code: M Exercise or conversion of derivative security

f1 disposition/acquisition made pursuant to a plan intended to comply with rule 10b5-1(c).


Filed on 2015-02-25 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-15-000021.txt Sec File: edgar/data/1487767/0001237899-15-000021-index.htm

2015-02-23 Aberman Michael S (CIK 1487767) through Direct (Svp Strategy Investor Relation)

Invested in Regeneron Pharmaceuticals Inc remaining shares owned 407

Common Stock Regeneron Pharmaceuticals Inc Regn


Filed on 2015-02-18 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-15-000014.txt Sec File: edgar/data/1487767/0001237899-15-000014-index.htm

2015-02-13 Aberman Michael S (CIK 1487767) through Direct (Svp Strategy Investor Relation)

Invested in Regeneron Pharmaceuticals Inc sold 7500.0 shares at $0.0 remaining shares owned 21668

Non-Qualified Stock Option Right To Buy Regeneron Pharmaceuticals Inc Regn exercise price 24.0 has valueitem expiration due date 2020-03-22 underlying security shares 7500 underlying security title Common Stock

f1 disposition/acquisition made pursuant to a plan intended to comply with rule 10b5-1(c).
f6 the stock option award (combined incentive stock option and non-qualified stock option) vests over five years, commencing one year after the date of grant. 12,500 options vest on the first anniversary, 25,000 options vest on the second anniversary, 25,000 options vest on the third anniversary, 25,000 options vest on the fourth anniversary, and 12,500 options vest on the fifth anniversary of the date of grant.


Filed on 2015-02-18 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-15-000014.txt Sec File: edgar/data/1487767/0001237899-15-000014-index.htm

2015-02-17 Aberman Michael S (CIK 1487767) through Direct (Svp Strategy Investor Relation)

Invested in Regeneron Pharmaceuticals Inc sold 100 shares at $406.24 remaining shares owned 18600

Common Stock Regeneron Pharmaceuticals Inc Regn Transaction code: S Open market or private sale of securities

f1 disposition/acquisition made pursuant to a plan intended to comply with rule 10b5-1(c).


Filed on 2015-02-18 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-15-000014.txt Sec File: edgar/data/1487767/0001237899-15-000014-index.htm

2015-02-17 Aberman Michael S (CIK 1487767) through Direct (Svp Strategy Investor Relation)

Invested in Regeneron Pharmaceuticals Inc sold 900 shares at $405.56 remaining shares owned 18700

Common Stock Regeneron Pharmaceuticals Inc Regn Transaction code: S Open market or private sale of securities

f1 disposition/acquisition made pursuant to a plan intended to comply with rule 10b5-1(c).
f5 represents volume-weighted average price of sales of 900 shares of company stock on february 17, 2015 at prices ranging from $405.09 to $405.97. upon request by the commission staff, the company, or a security holder of the company, the reporting person will provide full information regarding the number of shares sold by the reporting person on february 17, 2015 at each separate price.


Filed on 2015-02-18 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-15-000014.txt Sec File: edgar/data/1487767/0001237899-15-000014-index.htm

2015-02-17 Aberman Michael S (CIK 1487767) through Direct (Svp Strategy Investor Relation)

Invested in Regeneron Pharmaceuticals Inc sold 1692 shares at $404.55 remaining shares owned 19600

Common Stock Regeneron Pharmaceuticals Inc Regn Transaction code: S Open market or private sale of securities

f1 disposition/acquisition made pursuant to a plan intended to comply with rule 10b5-1(c).
f4 represents volume-weighted average price of sales of 1,692 shares of company stock on february 17, 2015 at prices ranging from $404.21 to $404.90. upon request by the commission staff, the company, or a security holder of the company, the reporting person will provide full information regarding the number of shares sold by the reporting person on february 17, 2015 at each separate price.


Filed on 2015-02-18 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-15-000014.txt Sec File: edgar/data/1487767/0001237899-15-000014-index.htm

2015-02-17 Aberman Michael S (CIK 1487767) through Direct (Svp Strategy Investor Relation)

Invested in Regeneron Pharmaceuticals Inc sold 600 shares at $403.72 remaining shares owned 21292

Common Stock Regeneron Pharmaceuticals Inc Regn Transaction code: S Open market or private sale of securities

f1 disposition/acquisition made pursuant to a plan intended to comply with rule 10b5-1(c).
f3 represents volume-weighted average price of sales of 600 shares of company stock on february 17, 2015 at prices ranging from $403.24 to $403.98. upon request by the commission staff, the company, or a security holder of the company, the reporting person will provide full information regarding the number of shares sold by the reporting person on february 17, 2015 at each separate price.


Filed on 2015-02-18 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-15-000014.txt Sec File: edgar/data/1487767/0001237899-15-000014-index.htm

2015-02-17 Aberman Michael S (CIK 1487767) through Direct (Svp Strategy Investor Relation)

Invested in Regeneron Pharmaceuticals Inc sold 300 shares at $402.51 remaining shares owned 21892

Common Stock Regeneron Pharmaceuticals Inc Regn Transaction code: S Open market or private sale of securities

f1 disposition/acquisition made pursuant to a plan intended to comply with rule 10b5-1(c).
f2 represents volume-weighted average price of sales of 300 shares of company stock on february 17, 2015 at prices ranging from $402.27 to $402.64. upon request by the commission staff, the company, or a security holder of the company, the reporting person will provide full information regarding the number of shares sold by the reporting person on february 17, 2015 at each separate price.


Filed on 2015-02-18 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-15-000014.txt Sec File: edgar/data/1487767/0001237899-15-000014-index.htm

2015-02-17 Aberman Michael S (CIK 1487767) through Direct (Svp Strategy Investor Relation)

Invested in Regeneron Pharmaceuticals Inc sold 100 shares at $401.54 remaining shares owned 22192

Common Stock Regeneron Pharmaceuticals Inc Regn Transaction code: S Open market or private sale of securities

f1 disposition/acquisition made pursuant to a plan intended to comply with rule 10b5-1(c).


Filed on 2015-02-18 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-15-000014.txt Sec File: edgar/data/1487767/0001237899-15-000014-index.htm

2015-02-13 Aberman Michael S (CIK 1487767) through Direct (Svp Strategy Investor Relation)

Invested in Regeneron Pharmaceuticals Inc sold 3361 shares at $402.05 remaining shares owned 22292

Common Stock Regeneron Pharmaceuticals Inc Regn Transaction code: F Payment of exercise price or tax liability by delivering or withholding securities

f1 disposition/acquisition made pursuant to a plan intended to comply with rule 10b5-1(c).


Filed on 2015-02-18 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-15-000014.txt Sec File: edgar/data/1487767/0001237899-15-000014-index.htm

2015-02-13 Aberman Michael S (CIK 1487767) through Direct (Svp Strategy Investor Relation)

Invested in Regeneron Pharmaceuticals Inc sold 447 shares at $402.05 remaining shares owned 25653

Common Stock Regeneron Pharmaceuticals Inc Regn Transaction code: F Payment of exercise price or tax liability by delivering or withholding securities

f1 disposition/acquisition made pursuant to a plan intended to comply with rule 10b5-1(c).


Filed on 2015-02-18 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-15-000014.txt Sec File: edgar/data/1487767/0001237899-15-000014-index.htm

2015-02-13 Aberman Michael S (CIK 1487767) through Direct (Svp Strategy Investor Relation)

Invested in Regeneron Pharmaceuticals Inc bought 7500 shares at $24.0 remaining shares owned 26100

Common Stock Regeneron Pharmaceuticals Inc Regn Transaction code: M Exercise or conversion of derivative security

f1 disposition/acquisition made pursuant to a plan intended to comply with rule 10b5-1(c).


Filed on 2015-02-18 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-15-000014.txt Sec File: edgar/data/1487767/0001237899-15-000014-index.htm

2015-02-13 Aberman Michael S (CIK 1487767) through Direct (Svp Strategy Investor Relation)

Invested in Regeneron Pharmaceuticals Inc remaining shares owned 376

Common Stock Regeneron Pharmaceuticals Inc Regn


Filed on 2014-12-18 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-14-000088.txt Sec File: edgar/data/1487767/0001237899-14-000088-index.htm

2014-12-16 Aberman Michael S (CIK 1487767) through Direct (Vp Strategy And Investor Relat)

Invested in Regeneron Pharmaceuticals Inc bought 30000.0 shares at $0.0 remaining shares owned 30000

Non-Qualified Stock Option Right To Buy Regeneron Pharmaceuticals Inc Regn exercise price 399.66 has valueitem expiration due date 2024-12-16 underlying security shares 30000 underlying security title Common Stock

f1 the stock option award vests in four equal annual installments, commencing one year after the date of grant.


Filed on 2014-08-26 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-14-000061.txt Sec File: edgar/data/1487767/0001237899-14-000061-index.htm

2014-08-22 Aberman Michael S (CIK 1487767) through Direct (Vp Strategy And Investor Relat)

Invested in Regeneron Pharmaceuticals Inc sold 3000.0 shares at $0.0 remaining shares owned 8064

Incentive Stock Option Right To Buy Regeneron Pharmaceuticals Inc Regn exercise price 24.0 has valueitem expiration due date 2020-03-22 underlying security shares 3000 underlying security title Common Stock

f1 the stock option award (combined incentive stock option and non-qualified stock option) vests over five years, commencing one year after the date of grant. 12,500 options vest on the first anniversary, 25,000 options vest on the second anniversary, 25,000 options vest on the third anniversary, 25,000 options vest on the fourth anniversary, and 12,500 options vest on the fifth anniversary of the date of grant.


Filed on 2014-08-26 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-14-000061.txt Sec File: edgar/data/1487767/0001237899-14-000061-index.htm

2014-08-22 Aberman Michael S (CIK 1487767) through Direct (Vp Strategy And Investor Relat)

Invested in Regeneron Pharmaceuticals Inc bought 3000 shares at $24.0 remaining shares owned 18600

Common Stock Regeneron Pharmaceuticals Inc Regn Transaction code: M Exercise or conversion of derivative security


Filed on 2014-08-26 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-14-000061.txt Sec File: edgar/data/1487767/0001237899-14-000061-index.htm

2014-08-22 Aberman Michael S (CIK 1487767) through Direct (Vp Strategy And Investor Relat)

Invested in Regeneron Pharmaceuticals Inc remaining shares owned 376

Common Stock Regeneron Pharmaceuticals Inc Regn


Filed on 2014-08-19 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-14-000060.txt Sec File: edgar/data/1487767/0001237899-14-000060-index.htm

2014-08-18 Aberman Michael S (CIK 1487767) through Direct (Vp Strategy And Investor Relat)

Invested in Regeneron Pharmaceuticals Inc sold 8750.0 shares at $0.0 remaining shares owned 26250

Non-Qualified Stock Option Right To Buy Regeneron Pharmaceuticals Inc Regn exercise price 52.03 has valueitem expiration due date 2021-12-16 underlying security shares 8750 underlying security title Common Stock

f1 disposition/acquisition made pursuant to a plan intended to comply with rule 10b5-1(c).
f2 the stock option award vests in four equal annual installments, commencing one year after the date of grant.


Filed on 2014-08-19 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-14-000060.txt Sec File: edgar/data/1487767/0001237899-14-000060-index.htm

2014-08-19 Aberman Michael S (CIK 1487767) through Direct (Vp Strategy And Investor Relat)

Invested in Regeneron Pharmaceuticals Inc sold 3611 shares at $350.0 remaining shares owned 15600

Common Stock Regeneron Pharmaceuticals Inc Regn Transaction code: S Open market or private sale of securities

f1 disposition/acquisition made pursuant to a plan intended to comply with rule 10b5-1(c).


Filed on 2014-08-19 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-14-000060.txt Sec File: edgar/data/1487767/0001237899-14-000060-index.htm

2014-08-18 Aberman Michael S (CIK 1487767) through Direct (Vp Strategy And Investor Relat)

Invested in Regeneron Pharmaceuticals Inc sold 3843 shares at $351.06 remaining shares owned 19211

Common Stock Regeneron Pharmaceuticals Inc Regn Transaction code: F Payment of exercise price or tax liability by delivering or withholding securities

f1 disposition/acquisition made pursuant to a plan intended to comply with rule 10b5-1(c).


Filed on 2014-08-19 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-14-000060.txt Sec File: edgar/data/1487767/0001237899-14-000060-index.htm

2014-08-18 Aberman Michael S (CIK 1487767) through Direct (Vp Strategy And Investor Relat)

Invested in Regeneron Pharmaceuticals Inc sold 1296 shares at $351.06 remaining shares owned 23054

Common Stock Regeneron Pharmaceuticals Inc Regn Transaction code: F Payment of exercise price or tax liability by delivering or withholding securities

f1 disposition/acquisition made pursuant to a plan intended to comply with rule 10b5-1(c).


Filed on 2014-08-19 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-14-000060.txt Sec File: edgar/data/1487767/0001237899-14-000060-index.htm

2014-08-18 Aberman Michael S (CIK 1487767) through Direct (Vp Strategy And Investor Relat)

Invested in Regeneron Pharmaceuticals Inc bought 8750 shares at $52.03 remaining shares owned 24350

Common Stock Regeneron Pharmaceuticals Inc Regn Transaction code: M Exercise or conversion of derivative security

f1 disposition/acquisition made pursuant to a plan intended to comply with rule 10b5-1(c).


Filed on 2014-08-19 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-14-000060.txt Sec File: edgar/data/1487767/0001237899-14-000060-index.htm

2014-08-18 Aberman Michael S (CIK 1487767) through Direct (Vp Strategy And Investor Relat)

Invested in Regeneron Pharmaceuticals Inc remaining shares owned 376

Common Stock Regeneron Pharmaceuticals Inc Regn


Filed on 2014-02-19 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-14-000023.txt Sec File: edgar/data/1487767/0001237899-14-000023-index.htm

2014-02-14 Aberman Michael S (CIK 1487767) through Direct (Vp Strategy And Investor Relat)

Invested in Regeneron Pharmaceuticals Inc sold 7500.0 shares at $0.0 remaining shares owned 15000

Non-Qualified Stock Option Right To Buy Regeneron Pharmaceuticals Inc Regn exercise price 30.63 has valueitem expiration due date 2020-12-14 underlying security shares 7500 underlying security title Common Stock

f1 disposition/acquisition made pursuant to a plan intended to comply with rule 10b5-1(c).
f10 the stock option award vests in four equal annual installments, commencing one year after the date of grant.


Filed on 2014-02-19 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-14-000023.txt Sec File: edgar/data/1487767/0001237899-14-000023-index.htm

2014-02-18 Aberman Michael S (CIK 1487767) through Direct (Vp Strategy And Investor Relat)

Invested in Regeneron Pharmaceuticals Inc sold 300 shares at $334.24 remaining shares owned 15600

Common Stock Regeneron Pharmaceuticals Inc Regn Transaction code: S Open market or private sale of securities

f1 disposition/acquisition made pursuant to a plan intended to comply with rule 10b5-1(c).
f9 represents volume-weighted average price of sales of 300 shares of company stock on february 18, 2014 at prices ranging from $334.00 to $334.41. upon request by the commission staff, the company, or a security holder of the company, the reporting person will provide full information regarding the number of shares sold by the reporting person on february 18, 2014 at each separate price.


Filed on 2014-02-19 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-14-000023.txt Sec File: edgar/data/1487767/0001237899-14-000023-index.htm

2014-02-18 Aberman Michael S (CIK 1487767) through Direct (Vp Strategy And Investor Relat)

Invested in Regeneron Pharmaceuticals Inc sold 948 shares at $333.5 remaining shares owned 15900

Common Stock Regeneron Pharmaceuticals Inc Regn Transaction code: S Open market or private sale of securities

f1 disposition/acquisition made pursuant to a plan intended to comply with rule 10b5-1(c).
f8 represents volume-weighted average price of sales of 948 shares of company stock on february 18, 2014 at prices ranging from $333.06 to $333.92. upon request by the commission staff, the company, or a security holder of the company, the reporting person will provide full information regarding the number of shares sold by the reporting person on february 18, 2014 at each separate price.


Filed on 2014-02-19 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-14-000023.txt Sec File: edgar/data/1487767/0001237899-14-000023-index.htm

2014-02-18 Aberman Michael S (CIK 1487767) through Direct (Vp Strategy And Investor Relat)

Invested in Regeneron Pharmaceuticals Inc sold 1100 shares at $332.41 remaining shares owned 16848

Common Stock Regeneron Pharmaceuticals Inc Regn Transaction code: S Open market or private sale of securities

f1 disposition/acquisition made pursuant to a plan intended to comply with rule 10b5-1(c).
f7 represents volume-weighted average price of sales of 1,100 shares of company stock on february 18, 2014 at prices ranging from $332.00 to $332.85. upon request by the commission staff, the company, or a security holder of the company, the reporting person will provide full information regarding the number of shares sold by the reporting person on february 18, 2014 at each separate price.


Filed on 2014-02-19 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-14-000023.txt Sec File: edgar/data/1487767/0001237899-14-000023-index.htm

2014-02-18 Aberman Michael S (CIK 1487767) through Direct (Vp Strategy And Investor Relat)

Invested in Regeneron Pharmaceuticals Inc sold 200 shares at $331.16 remaining shares owned 17948

Common Stock Regeneron Pharmaceuticals Inc Regn Transaction code: S Open market or private sale of securities

f1 disposition/acquisition made pursuant to a plan intended to comply with rule 10b5-1(c).
f6 represents volume-weighted average price of sales of 200 shares of company stock on february 18, 2014 at prices ranging from $331.01 to $331.31. upon request by the commission staff, the company, or a security holder of the company, the reporting person will provide full information regarding the number of shares sold by the reporting person on february 18, 2014 at each separate price.


Filed on 2014-02-19 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-14-000023.txt Sec File: edgar/data/1487767/0001237899-14-000023-index.htm

2014-02-18 Aberman Michael S (CIK 1487767) through Direct (Vp Strategy And Investor Relat)

Invested in Regeneron Pharmaceuticals Inc sold 200 shares at $330.87 remaining shares owned 18148

Common Stock Regeneron Pharmaceuticals Inc Regn Transaction code: S Open market or private sale of securities

f1 disposition/acquisition made pursuant to a plan intended to comply with rule 10b5-1(c).
f5 represents volume-weighted average price of sales of 200 shares of company stock on february 18, 2014 at prices ranging from $330.82 to $330.91. upon request by the commission staff, the company, or a security holder of the company, the reporting person will provide full information regarding the number of shares sold by the reporting person on february 18, 2014 at each separate price.


Filed on 2014-02-19 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-14-000023.txt Sec File: edgar/data/1487767/0001237899-14-000023-index.htm

2014-02-18 Aberman Michael S (CIK 1487767) through Direct (Vp Strategy And Investor Relat)

Invested in Regeneron Pharmaceuticals Inc sold 200 shares at $329.34 remaining shares owned 18348

Common Stock Regeneron Pharmaceuticals Inc Regn Transaction code: S Open market or private sale of securities

f1 disposition/acquisition made pursuant to a plan intended to comply with rule 10b5-1(c).
f4 represents volume-weighted average price of sales of 200 shares of company stock on february 18, 2014 at prices ranging from $329.05 to $329.63. upon request by the commission staff, the company, or a security holder of the company, the reporting person will provide full information regarding the number of shares sold by the reporting person on february 18, 2014 at each separate price.


Filed on 2014-02-19 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-14-000023.txt Sec File: edgar/data/1487767/0001237899-14-000023-index.htm

2014-02-18 Aberman Michael S (CIK 1487767) through Direct (Vp Strategy And Investor Relat)

Invested in Regeneron Pharmaceuticals Inc sold 100 shares at $328.6 remaining shares owned 18548

Common Stock Regeneron Pharmaceuticals Inc Regn Transaction code: S Open market or private sale of securities

f1 disposition/acquisition made pursuant to a plan intended to comply with rule 10b5-1(c).


Filed on 2014-02-19 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-14-000023.txt Sec File: edgar/data/1487767/0001237899-14-000023-index.htm

2014-02-18 Aberman Michael S (CIK 1487767) through Direct (Vp Strategy And Investor Relat)

Invested in Regeneron Pharmaceuticals Inc sold 300 shares at $327.56 remaining shares owned 18648

Common Stock Regeneron Pharmaceuticals Inc Regn Transaction code: S Open market or private sale of securities

f1 disposition/acquisition made pursuant to a plan intended to comply with rule 10b5-1(c).
f3 represents volume-weighted average price of sales of 300 shares of company stock on february 18, 2014 at prices ranging from $327.00 to $327.85. upon request by the commission staff, the company, or a security holder of the company, the reporting person will provide full information regarding the number of shares sold by the reporting person on february 18, 2014 at each separate price.


Filed on 2014-02-19 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-14-000023.txt Sec File: edgar/data/1487767/0001237899-14-000023-index.htm

2014-02-18 Aberman Michael S (CIK 1487767) through Direct (Vp Strategy And Investor Relat)

Invested in Regeneron Pharmaceuticals Inc sold 200 shares at $325.36 remaining shares owned 18948

Common Stock Regeneron Pharmaceuticals Inc Regn Transaction code: S Open market or private sale of securities

f1 disposition/acquisition made pursuant to a plan intended to comply with rule 10b5-1(c).
f2 represents volume-weighted average price of sales of 200 shares of company stock on february 18, 2014 at prices ranging from $325.11 to $325.61. upon request by the commission staff, the company, or a security holder of the company, the reporting person will provide full information regarding the number of shares sold by the reporting person on february 18, 2014 at each separate price.


Filed on 2014-02-19 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-14-000023.txt Sec File: edgar/data/1487767/0001237899-14-000023-index.htm

2014-02-18 Aberman Michael S (CIK 1487767) through Direct (Vp Strategy And Investor Relat)

Invested in Regeneron Pharmaceuticals Inc sold 100 shares at $324.81 remaining shares owned 19148

Common Stock Regeneron Pharmaceuticals Inc Regn Transaction code: S Open market or private sale of securities

f1 disposition/acquisition made pursuant to a plan intended to comply with rule 10b5-1(c).


Filed on 2014-02-19 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-14-000023.txt Sec File: edgar/data/1487767/0001237899-14-000023-index.htm

2014-02-14 Aberman Michael S (CIK 1487767) through Direct (Vp Strategy And Investor Relat)

Invested in Regeneron Pharmaceuticals Inc sold 3142 shares at $323.3 remaining shares owned 19248

Common Stock Regeneron Pharmaceuticals Inc Regn Transaction code: F Payment of exercise price or tax liability by delivering or withholding securities

f1 disposition/acquisition made pursuant to a plan intended to comply with rule 10b5-1(c).


Filed on 2014-02-19 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-14-000023.txt Sec File: edgar/data/1487767/0001237899-14-000023-index.htm

2014-02-14 Aberman Michael S (CIK 1487767) through Direct (Vp Strategy And Investor Relat)

Invested in Regeneron Pharmaceuticals Inc sold 710 shares at $323.3 remaining shares owned 22390

Common Stock Regeneron Pharmaceuticals Inc Regn Transaction code: F Payment of exercise price or tax liability by delivering or withholding securities

f1 disposition/acquisition made pursuant to a plan intended to comply with rule 10b5-1(c).


Filed on 2014-02-19 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-14-000023.txt Sec File: edgar/data/1487767/0001237899-14-000023-index.htm

2014-02-14 Aberman Michael S (CIK 1487767) through Direct (Vp Strategy And Investor Relat)

Invested in Regeneron Pharmaceuticals Inc bought 7500 shares at $30.63 remaining shares owned 23100

Common Stock Regeneron Pharmaceuticals Inc Regn Transaction code: M Exercise or conversion of derivative security

f1 disposition/acquisition made pursuant to a plan intended to comply with rule 10b5-1(c).


Filed on 2014-02-19 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-14-000023.txt Sec File: edgar/data/1487767/0001237899-14-000023-index.htm

2014-02-14 Aberman Michael S (CIK 1487767) through Direct (Vp Strategy And Investor Relat)

Invested in Regeneron Pharmaceuticals Inc remaining shares owned 376

Common Stock Regeneron Pharmaceuticals Inc Regn


Filed on 2013-12-17 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-13-000066.txt Sec File: edgar/data/1487767/0001237899-13-000066-index.htm

2013-12-13 Aberman Michael S (CIK 1487767) through Direct (Vp Strategy And Investor Relat)

Invested in Regeneron Pharmaceuticals Inc bought 30000.0 shares at $0.0 remaining shares owned 30000

Non-Qualified Stock Option Right To Buy Regeneron Pharmaceuticals Inc Regn exercise price 270.43 has valueitem expiration due date 2023-12-13 underlying security shares 30000 underlying security title Common Stock

f1 the stock option award vests in four equal annual installments, commencing one year after the date of grant.


Filed on 2013-06-18 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-13-000044.txt Sec File: edgar/data/1487767/0001237899-13-000044-index.htm

2013-06-17 Aberman Michael S (CIK 1487767) through Direct (Vp Strategy And Investor Relat)

Invested in Regeneron Pharmaceuticals Inc sold 3900.0 shares remaining shares owned 11064

Incentive Stock Option Right To Buy Regeneron Pharmaceuticals Inc Regn exercise price 24.0 has valueitem expiration due date 2020-03-22 underlying security shares 3900 underlying security title Common Stock

f2 exercisable date, exercise date, exercise price, purchase price, sales price, and/or expiration date is/are not applicable in this case.
f1 the stock option award (combined incentive stock option and non-qualified stock option) vests over five years, commencing one year after the date of grant. 12,500 options vest on the first anniversary, 25,000 options vest on the second anniversary, 25,000 options vest on the third anniversary, 25,000 options vest on the fourth anniversary, and 12,500 options vest on the fifth anniversary of the date of grant.


Filed on 2013-06-18 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-13-000044.txt Sec File: edgar/data/1487767/0001237899-13-000044-index.htm

2013-06-17 Aberman Michael S (CIK 1487767) through Direct (Vp Strategy And Investor Relat)

Invested in Regeneron Pharmaceuticals Inc bought 3900 shares at $24.0 remaining shares owned 15600

Common Stock Regeneron Pharmaceuticals Inc Regn Transaction code: M Exercise or conversion of derivative security


Filed on 2013-06-18 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-13-000044.txt Sec File: edgar/data/1487767/0001237899-13-000044-index.htm

2013-06-17 Aberman Michael S (CIK 1487767) through Direct (Vp Strategy And Investor Relat)

Invested in Regeneron Pharmaceuticals Inc remaining shares owned 344

Common Stock Regeneron Pharmaceuticals Inc Regn


Filed on 2013-05-15 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-13-000035.txt Sec File: edgar/data/1487767/0001237899-13-000035-index.htm

2013-05-13 Aberman Michael S (CIK 1487767) through Direct (Vp Strategy And Investor Relat)

Invested in Regeneron Pharmaceuticals Inc sold 12500.0 shares remaining shares owned 29168

Non-Qualified Stock Option Right To Buy Regeneron Pharmaceuticals Inc Regn exercise price 24.0 has valueitem expiration due date 2020-03-22 underlying security shares 12500 underlying security title Common Stock

f1 disposition/acquisition made pursuant to a plan intended to comply with rule 10b5-1(c).
f6 exercisable date, exercise date, exercise price, purchase price, sales price, and/or expiration date is/are not applicable in this case.
f5 the stock option award (combined incentive stock option and non-qualified stock option) vests over five years, commencing one year after the date of grant. 12,500 options vest on the first anniversary, 25,000 options vest on the second anniversary, 25,000 options vest on the third anniversary, 25,000 options vest on the fourth anniversary, and 12,500 options vest on the fifth anniversary of the date of grant.


Filed on 2013-05-15 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-13-000035.txt Sec File: edgar/data/1487767/0001237899-13-000035-index.htm

2013-05-14 Aberman Michael S (CIK 1487767) through Direct (Vp Strategy And Investor Relat)

Invested in Regeneron Pharmaceuticals Inc sold 100 shares at $281.72 remaining shares owned 11700

Common Stock Regeneron Pharmaceuticals Inc Regn Transaction code: S Open market or private sale of securities

f1 disposition/acquisition made pursuant to a plan intended to comply with rule 10b5-1(c).


Filed on 2013-05-15 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-13-000035.txt Sec File: edgar/data/1487767/0001237899-13-000035-index.htm

2013-05-14 Aberman Michael S (CIK 1487767) through Direct (Vp Strategy And Investor Relat)

Invested in Regeneron Pharmaceuticals Inc sold 1263 shares at $280.4 remaining shares owned 11800

Common Stock Regeneron Pharmaceuticals Inc Regn Transaction code: S Open market or private sale of securities

f1 disposition/acquisition made pursuant to a plan intended to comply with rule 10b5-1(c).
f4 represents volume-weighted average price of sales of 1,263 shares of company stock on may 14, 2013 at prices ranging from $280.04 to $280.79. upon request by the commission staff, the company, or a security holder of the company, the reporting person will provide full information regarding the number of shares sold by the reporting person on may 14, 2013 at each separate price.


Filed on 2013-05-15 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-13-000035.txt Sec File: edgar/data/1487767/0001237899-13-000035-index.htm

2013-05-14 Aberman Michael S (CIK 1487767) through Direct (Vp Strategy And Investor Relat)

Invested in Regeneron Pharmaceuticals Inc sold 3465 shares at $279.44 remaining shares owned 13063

Common Stock Regeneron Pharmaceuticals Inc Regn Transaction code: S Open market or private sale of securities

f1 disposition/acquisition made pursuant to a plan intended to comply with rule 10b5-1(c).
f3 represents volume-weighted average price of sales of 3,465 shares of company stock on may 14, 2013 at prices ranging from $279.00 to $279.99. upon request by the commission staff, the company, or a security holder of the company, the reporting person will provide full information regarding the number of shares sold by the reporting person on may 14, 2013 at each separate price.


Filed on 2013-05-15 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-13-000035.txt Sec File: edgar/data/1487767/0001237899-13-000035-index.htm

2013-05-14 Aberman Michael S (CIK 1487767) through Direct (Vp Strategy And Investor Relat)

Invested in Regeneron Pharmaceuticals Inc sold 701 shares at $278.72 remaining shares owned 16528

Common Stock Regeneron Pharmaceuticals Inc Regn Transaction code: S Open market or private sale of securities

f1 disposition/acquisition made pursuant to a plan intended to comply with rule 10b5-1(c).
f2 represents volume-weighted average price of sales of 701 shares of company stock on may 14, 2013 at prices ranging from $278.19 to $278.94. upon request by the commission staff, the company, or a security holder of the company, the reporting person will provide full information regarding the number of shares sold by the reporting person on may 14, 2013 at each separate price.


Filed on 2013-05-15 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-13-000035.txt Sec File: edgar/data/1487767/0001237899-13-000035-index.htm

2013-05-13 Aberman Michael S (CIK 1487767) through Direct (Vp Strategy And Investor Relat)

Invested in Regeneron Pharmaceuticals Inc sold 5885 shares at $275.97 remaining shares owned 17229

Common Stock Regeneron Pharmaceuticals Inc Regn Transaction code: F Payment of exercise price or tax liability by delivering or withholding securities

f1 disposition/acquisition made pursuant to a plan intended to comply with rule 10b5-1(c).


Filed on 2013-05-15 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-13-000035.txt Sec File: edgar/data/1487767/0001237899-13-000035-index.htm

2013-05-13 Aberman Michael S (CIK 1487767) through Direct (Vp Strategy And Investor Relat)

Invested in Regeneron Pharmaceuticals Inc sold 1086 shares at $275.97 remaining shares owned 23114

Common Stock Regeneron Pharmaceuticals Inc Regn Transaction code: F Payment of exercise price or tax liability by delivering or withholding securities

f1 disposition/acquisition made pursuant to a plan intended to comply with rule 10b5-1(c).


Filed on 2013-05-15 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-13-000035.txt Sec File: edgar/data/1487767/0001237899-13-000035-index.htm

2013-05-13 Aberman Michael S (CIK 1487767) through Direct (Vp Strategy And Investor Relat)

Invested in Regeneron Pharmaceuticals Inc bought 12500 shares at $24.0 remaining shares owned 24200

Common Stock Regeneron Pharmaceuticals Inc Regn Transaction code: M Exercise or conversion of derivative security

f1 disposition/acquisition made pursuant to a plan intended to comply with rule 10b5-1(c).


Filed on 2013-05-15 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-13-000035.txt Sec File: edgar/data/1487767/0001237899-13-000035-index.htm

2013-05-13 Aberman Michael S (CIK 1487767) through Direct (Vp Strategy And Investor Relat)

Invested in Regeneron Pharmaceuticals Inc remaining shares owned 344

Common Stock Regeneron Pharmaceuticals Inc Regn


Filed on 2013-05-08 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-13-000031.txt Sec File: edgar/data/1487767/0001237899-13-000031-index.htm

2013-05-06 Aberman Michael S (CIK 1487767) through Direct (Vp Strategy And Investor Relat)

Invested in Regeneron Pharmaceuticals Inc sold 1600.0 shares remaining shares owned 41668

Non-Qualified Stock Option Right To Buy Regeneron Pharmaceuticals Inc Regn exercise price 24.0 has valueitem expiration due date 2020-03-22 underlying security shares 1600 underlying security title Common Stock

f4 exercisable date, exercise date, exercise price, purchase price, sales price, and/or expiration date is/are not applicable in this case.
f3 the stock option award (combined incentive stock option and non-qualified stock option) vests over five years, commencing one year after the date of grant. 12,500 options vest on the first anniversary, 25,000 options vest on the second anniversary, 25,000 options vest on the third anniversary, 25,000 options vest on the fourth anniversary, and 12,500 options vest on the fifth anniversary of the date of grant.


Filed on 2013-05-08 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-13-000031.txt Sec File: edgar/data/1487767/0001237899-13-000031-index.htm

2013-05-06 Aberman Michael S (CIK 1487767) through Direct (Vp Strategy And Investor Relat)

Invested in Regeneron Pharmaceuticals Inc sold 6734.0 shares remaining shares owned 43268

Non-Qualified Stock Option Right To Buy Regeneron Pharmaceuticals Inc Regn exercise price 24.0 has valueitem expiration due date 2020-03-22 underlying security shares 6734 underlying security title Common Stock

f4 exercisable date, exercise date, exercise price, purchase price, sales price, and/or expiration date is/are not applicable in this case.
f3 the stock option award (combined incentive stock option and non-qualified stock option) vests over five years, commencing one year after the date of grant. 12,500 options vest on the first anniversary, 25,000 options vest on the second anniversary, 25,000 options vest on the third anniversary, 25,000 options vest on the fourth anniversary, and 12,500 options vest on the fifth anniversary of the date of grant.


Filed on 2013-05-08 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-13-000031.txt Sec File: edgar/data/1487767/0001237899-13-000031-index.htm

2013-05-06 Aberman Michael S (CIK 1487767) through Direct (Vp Strategy And Investor Relat)

Invested in Regeneron Pharmaceuticals Inc sold 1600 shares at $256.46 remaining shares owned 11700

Common Stock Regeneron Pharmaceuticals Inc Regn Transaction code: S Open market or private sale of securities

f2 represents volume-weighted average price of sales of 6,734 shares of company stock on may 6, 2013 at prices ranging from $257.00 to $257.62. upon request by the commission staff, the company, or a security holder of the company, the reporting person will provide full information regarding the number of shares sold by the reporting person on may 6, 2013 at each separate price.


Filed on 2013-05-08 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-13-000031.txt Sec File: edgar/data/1487767/0001237899-13-000031-index.htm

2013-05-06 Aberman Michael S (CIK 1487767) through Direct (Vp Strategy And Investor Relat)

Invested in Regeneron Pharmaceuticals Inc bought 1600 shares at $24.0 remaining shares owned 13300

Common Stock Regeneron Pharmaceuticals Inc Regn Transaction code: M Exercise or conversion of derivative security


Filed on 2013-05-08 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-13-000031.txt Sec File: edgar/data/1487767/0001237899-13-000031-index.htm

2013-05-06 Aberman Michael S (CIK 1487767) through Direct (Vp Strategy And Investor Relat)

Invested in Regeneron Pharmaceuticals Inc sold 6734 shares at $257.29 remaining shares owned 11700

Common Stock Regeneron Pharmaceuticals Inc Regn Transaction code: S Open market or private sale of securities

f1 represents volume-weighted average price of sales of 1,600 shares of company stock on may 6, 2013 at prices ranging from $256.01 to $256.85. upon request by the commission staff, the company, or a security holder of the company, the reporting person will provide full information regarding the number of shares sold by the reporting person on may 6, 2013 at each separate price.


Filed on 2013-05-08 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-13-000031.txt Sec File: edgar/data/1487767/0001237899-13-000031-index.htm

2013-05-06 Aberman Michael S (CIK 1487767) through Direct (Vp Strategy And Investor Relat)

Invested in Regeneron Pharmaceuticals Inc bought 6734 shares at $24.0 remaining shares owned 18434

Common Stock Regeneron Pharmaceuticals Inc Regn Transaction code: M Exercise or conversion of derivative security


Filed on 2013-05-08 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-13-000031.txt Sec File: edgar/data/1487767/0001237899-13-000031-index.htm

2013-05-06 Aberman Michael S (CIK 1487767) through Direct (Vp Strategy And Investor Relat)

Invested in Regeneron Pharmaceuticals Inc remaining shares owned 344

Common Stock Regeneron Pharmaceuticals Inc Regn


Filed on 2012-12-19 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-12-000108.txt Sec File: edgar/data/1487767/0001237899-12-000108-index.htm

2012-12-18 Aberman Michael S (CIK 1487767) through Direct (Vp Strategy And Investor Relat)

Invested in Regeneron Pharmaceuticals Inc sold 1200.0 shares remaining shares owned 14964

Incentive Stock Option Right To Buy Regeneron Pharmaceuticals Inc Regn exercise price 24.0 has valueitem expiration due date 2020-03-22 underlying security shares 1200.0 underlying security title Common Stock

f2 exercisable date, exercise date, exercise price, purchase price, sales price, and/or expiration date is/are not applicable in this case.
f1 the stock option award (combined incentive stock option and non-qualified stock option) vests over five years, commencing one year after the date of grant. 12,500 options vest on the first anniversary, 25,000 options vest on the second anniversary, 25,000 options vest on the third anniversary, 25,000 options vest on the fourth anniversary, and 12,500 options vest on the fifth anniversary of the date of grant.


Filed on 2012-12-19 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-12-000108.txt Sec File: edgar/data/1487767/0001237899-12-000108-index.htm

2012-12-18 Aberman Michael S (CIK 1487767) through Direct (Vp Strategy And Investor Relat)

Invested in Regeneron Pharmaceuticals Inc bought 1200 shares at $24.0 remaining shares owned 11700

Common Stock Regeneron Pharmaceuticals Inc Regn Transaction code: M Exercise or conversion of derivative security


Filed on 2012-12-19 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-12-000108.txt Sec File: edgar/data/1487767/0001237899-12-000108-index.htm

2012-12-18 Aberman Michael S (CIK 1487767) through Direct (Vp Strategy And Investor Relat)

Invested in Regeneron Pharmaceuticals Inc remaining shares owned 287

Common Stock Regeneron Pharmaceuticals Inc Regn


Filed on 2012-12-17 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-12-000095.txt Sec File: edgar/data/1487767/0001237899-12-000095-index.htm

2012-12-14 Aberman Michael S (CIK 1487767) through Direct (Vp Strategy And Investor Relat)

Invested in Regeneron Pharmaceuticals Inc bought 35000.0 shares remaining shares owned 35000

Non-Qualified Stock Option Right To Buy Regeneron Pharmaceuticals Inc Regn exercise price 179.13 has valueitem expiration due date 2022-12-14 underlying security shares 35000.0 underlying security title Common Stock

f2 exercisable date, exercise date, exercise price, purchase price, sales price, and/or expiration date is/are not applicable in this case.
f1 the stock option award vests in four equal annual installments, commencing one year after the date of grant.


Filed on 2012-12-12 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-12-000094.txt Sec File: edgar/data/1487767/0001237899-12-000094-index.htm

2012-12-10 Aberman Michael S (CIK 1487767) through Direct (Vp Strategy And Investor Relat)

Invested in Regeneron Pharmaceuticals Inc sold 7500.0 shares remaining shares owned 22500

Non-Qualified Stock Option Right To Buy Regeneron Pharmaceuticals Inc Regn exercise price 30.63 has valueitem expiration due date 2020-12-14 underlying security shares 7500.0 underlying security title Common Stock

f1 disposition/acquisition made pursuant to a plan intended to comply with rule 10b5-1(c).
f5 exercisable date, exercise date, exercise price, purchase price, sales price, and/or expiration date is/are not applicable in this case.
f4 the stock option award vests in four equal annual installments, commencing one year after the date of grant.


Filed on 2012-12-12 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-12-000094.txt Sec File: edgar/data/1487767/0001237899-12-000094-index.htm

2012-12-11 Aberman Michael S (CIK 1487767) through Direct (Vp Strategy And Investor Relat)

Invested in Regeneron Pharmaceuticals Inc sold 2100 shares at $185.18 remaining shares owned 10500

Common Stock Regeneron Pharmaceuticals Inc Regn Transaction code: S Open market or private sale of securities

f1 disposition/acquisition made pursuant to a plan intended to comply with rule 10b5-1(c).
f3 represents volume-weighted average price of sales of 2,100 shares of company stock on december 11, 2012 at prices ranging from $185.00 to $185.50. upon request by the commission staff, the company, or a security holder of the company, the reporting person will provide full information regarding the number of shares sold by the reporting person on december 11, 2012 at each separate price.


Filed on 2012-12-12 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-12-000094.txt Sec File: edgar/data/1487767/0001237899-12-000094-index.htm

2012-12-11 Aberman Michael S (CIK 1487767) through Direct (Vp Strategy And Investor Relat)

Invested in Regeneron Pharmaceuticals Inc sold 1268 shares at $184.85 remaining shares owned 12600

Common Stock Regeneron Pharmaceuticals Inc Regn Transaction code: S Open market or private sale of securities

f1 disposition/acquisition made pursuant to a plan intended to comply with rule 10b5-1(c).
f2 represents volume-weighted average price of sales of 1,268 shares of company stock on december 11, 2012 at prices ranging from $184.63 to $184.99. upon request by the commission staff, the company, or a security holder of the company, the reporting person will provide full information regarding the number of shares sold by the reporting person on december 11, 2012 at each separate price.


Filed on 2012-12-12 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-12-000094.txt Sec File: edgar/data/1487767/0001237899-12-000094-index.htm

2012-12-10 Aberman Michael S (CIK 1487767) through Direct (Vp Strategy And Investor Relat)

Invested in Regeneron Pharmaceuticals Inc sold 2875 shares at $182.68 remaining shares owned 13868

Common Stock Regeneron Pharmaceuticals Inc Regn Transaction code: F Payment of exercise price or tax liability by delivering or withholding securities

f1 disposition/acquisition made pursuant to a plan intended to comply with rule 10b5-1(c).


Filed on 2012-12-12 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-12-000094.txt Sec File: edgar/data/1487767/0001237899-12-000094-index.htm

2012-12-10 Aberman Michael S (CIK 1487767) through Direct (Vp Strategy And Investor Relat)

Invested in Regeneron Pharmaceuticals Inc sold 1257 shares at $182.68 remaining shares owned 16743

Common Stock Regeneron Pharmaceuticals Inc Regn Transaction code: F Payment of exercise price or tax liability by delivering or withholding securities

f1 disposition/acquisition made pursuant to a plan intended to comply with rule 10b5-1(c).


Filed on 2012-12-12 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-12-000094.txt Sec File: edgar/data/1487767/0001237899-12-000094-index.htm

2012-12-10 Aberman Michael S (CIK 1487767) through Direct (Vp Strategy And Investor Relat)

Invested in Regeneron Pharmaceuticals Inc bought 7500 shares at $30.63 remaining shares owned 18000

Common Stock Regeneron Pharmaceuticals Inc Regn Transaction code: M Exercise or conversion of derivative security

f1 disposition/acquisition made pursuant to a plan intended to comply with rule 10b5-1(c).


Filed on 2012-12-12 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-12-000094.txt Sec File: edgar/data/1487767/0001237899-12-000094-index.htm

2012-12-10 Aberman Michael S (CIK 1487767) through Direct (Vp Strategy And Investor Relat)

Invested in Regeneron Pharmaceuticals Inc remaining shares owned 287

Common Stock Regeneron Pharmaceuticals Inc Regn


Filed on 2012-12-03 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-12-000092.txt Sec File: edgar/data/1487767/0001237899-12-000092-index.htm

2012-11-29 Aberman Michael S (CIK 1487767) through Direct (Vp Strategy And Investor Relat)

Invested in Regeneron Pharmaceuticals Inc sold 8334.0 shares remaining shares owned 50002

Non-Qualified Stock Option Right To Buy Regeneron Pharmaceuticals Inc Regn exercise price 24.0 has valueitem expiration due date 2020-03-22 underlying security shares 8334.0 underlying security title Common Stock

f1 disposition/acquisition made pursuant to a plan intended to comply with rule 10b5-1(c).
f7 exercisable date, exercise date, exercise price, purchase price, sales price, and/or expiration date is/are not applicable in this case.
f6 the stock option award (combined incentive stock option and non-qualified stock option) vests over five years, commencing one year after the date of grant. 12,500 options vest on the first anniversary, 25,000 options vest on the second anniversary, 25,000 options vest on the third anniversary, 25,000 options vest on the fourth anniversary, and 12,500 options vest on the fifth anniversary of the date of grant.


Filed on 2012-12-03 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-12-000092.txt Sec File: edgar/data/1487767/0001237899-12-000092-index.htm

2012-11-30 Aberman Michael S (CIK 1487767) through Direct (Vp Strategy And Investor Relat)

Invested in Regeneron Pharmaceuticals Inc sold 100 shares at $184.0 remaining shares owned 10500

Common Stock Regeneron Pharmaceuticals Inc Regn Transaction code: S Open market or private sale of securities

f1 disposition/acquisition made pursuant to a plan intended to comply with rule 10b5-1(c).


Filed on 2012-12-03 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-12-000092.txt Sec File: edgar/data/1487767/0001237899-12-000092-index.htm

2012-11-30 Aberman Michael S (CIK 1487767) through Direct (Vp Strategy And Investor Relat)

Invested in Regeneron Pharmaceuticals Inc sold 200 shares at $183.77 remaining shares owned 10600

Common Stock Regeneron Pharmaceuticals Inc Regn Transaction code: S Open market or private sale of securities

f1 disposition/acquisition made pursuant to a plan intended to comply with rule 10b5-1(c).
f5 represents volume-weighted average price of sales of 200 shares of company stock on november 30, 2012 at prices ranging from $183.64 to $183.89. upon request by the commission staff, the company, or a security holder of the company, the reporting person will provide full information regarding the number of shares sold by the reporting person on november 30, 2012 at each separate price.


Filed on 2012-12-03 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-12-000092.txt Sec File: edgar/data/1487767/0001237899-12-000092-index.htm

2012-11-30 Aberman Michael S (CIK 1487767) through Direct (Vp Strategy And Investor Relat)

Invested in Regeneron Pharmaceuticals Inc sold 200 shares at $182.39 remaining shares owned 10800

Common Stock Regeneron Pharmaceuticals Inc Regn Transaction code: S Open market or private sale of securities

f1 disposition/acquisition made pursuant to a plan intended to comply with rule 10b5-1(c).
f4 represents volume-weighted average price of sales of 200 shares of company stock on november 30, 2012 at prices ranging from $182.38 to $182.40. upon request by the commission staff, the company, or a security holder of the company, the reporting person will provide full information regarding the number of shares sold by the reporting person on november 30, 2012 at each separate price.


Filed on 2012-12-03 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-12-000092.txt Sec File: edgar/data/1487767/0001237899-12-000092-index.htm

2012-11-30 Aberman Michael S (CIK 1487767) through Direct (Vp Strategy And Investor Relat)

Invested in Regeneron Pharmaceuticals Inc sold 400 shares at $181.59 remaining shares owned 11000

Common Stock Regeneron Pharmaceuticals Inc Regn Transaction code: S Open market or private sale of securities

f1 disposition/acquisition made pursuant to a plan intended to comply with rule 10b5-1(c).
f3 represents volume-weighted average price of sales of 400 shares of company stock on november 30, 2012 at prices ranging from $181.29 to $181.76. upon request by the commission staff, the company, or a security holder of the company, the reporting person will provide full information regarding the number of shares sold by the reporting person on november 30, 2012 at each separate price.


Filed on 2012-12-03 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-12-000092.txt Sec File: edgar/data/1487767/0001237899-12-000092-index.htm

2012-11-30 Aberman Michael S (CIK 1487767) through Direct (Vp Strategy And Investor Relat)

Invested in Regeneron Pharmaceuticals Inc sold 3004 shares at $180.08 remaining shares owned 11400

Common Stock Regeneron Pharmaceuticals Inc Regn Transaction code: S Open market or private sale of securities

f1 disposition/acquisition made pursuant to a plan intended to comply with rule 10b5-1(c).
f2 represents volume-weighted average price of sales of 3,004 shares of company stock on november 30, 2012 at prices ranging from $180.00 to $180.97. upon request by the commission staff, the company, or a security holder of the company, the reporting person will provide full information regarding the number of shares sold by the reporting person on november 30, 2012 at each separate price.


Filed on 2012-12-03 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-12-000092.txt Sec File: edgar/data/1487767/0001237899-12-000092-index.htm

2012-11-29 Aberman Michael S (CIK 1487767) through Direct (Vp Strategy And Investor Relat)

Invested in Regeneron Pharmaceuticals Inc sold 3333 shares at $182.2 remaining shares owned 14404

Common Stock Regeneron Pharmaceuticals Inc Regn Transaction code: F Payment of exercise price or tax liability by delivering or withholding securities

f1 disposition/acquisition made pursuant to a plan intended to comply with rule 10b5-1(c).


Filed on 2012-12-03 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-12-000092.txt Sec File: edgar/data/1487767/0001237899-12-000092-index.htm

2012-11-29 Aberman Michael S (CIK 1487767) through Direct (Vp Strategy And Investor Relat)

Invested in Regeneron Pharmaceuticals Inc sold 1097 shares at $182.2 remaining shares owned 17737

Common Stock Regeneron Pharmaceuticals Inc Regn Transaction code: F Payment of exercise price or tax liability by delivering or withholding securities

f1 disposition/acquisition made pursuant to a plan intended to comply with rule 10b5-1(c).


Filed on 2012-12-03 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-12-000092.txt Sec File: edgar/data/1487767/0001237899-12-000092-index.htm

2012-11-29 Aberman Michael S (CIK 1487767) through Direct (Vp Strategy And Investor Relat)

Invested in Regeneron Pharmaceuticals Inc bought 8334 shares at $24.0 remaining shares owned 18834

Common Stock Regeneron Pharmaceuticals Inc Regn Transaction code: M Exercise or conversion of derivative security

f1 disposition/acquisition made pursuant to a plan intended to comply with rule 10b5-1(c).


Filed on 2012-12-03 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-12-000092.txt Sec File: edgar/data/1487767/0001237899-12-000092-index.htm

2012-11-29 Aberman Michael S (CIK 1487767) through Direct (Vp Strategy And Investor Relat)

Invested in Regeneron Pharmaceuticals Inc remaining shares owned 287

Common Stock Regeneron Pharmaceuticals Inc Regn


Filed on 2012-05-25 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-12-000058.txt Sec File: edgar/data/1487767/0001237899-12-000058-index.htm

2012-05-24 Aberman Michael S (CIK 1487767) through Direct (Vp Strategy And Investor Relat)

Invested in Regeneron Pharmaceuticals Inc sold 500.0 shares remaining shares owned 16164

Incentive Stock Option Right To Buy Regeneron Pharmaceuticals Inc Regn exercise price 24.0 has valueitem expiration due date 2020-03-22 underlying security shares 500.0 underlying security title Common Stock

f2 exercisable date, exercise date, exercise price, purchase price, sales price, and/or expiration date is/are not applicable in this case.
f1 the stock option award (combined incentive stock option and non-qualified stock option) vests over five years, commencing one year after the date of grant. 12,500 options vest on the first anniversary, 25,000 options vest on the second anniversary, 25,000 options vest on the third anniversary, 25,000 options vest on the fourth anniversary, and 12,500 options vest on the fifth anniversary of the date of grant.


Filed on 2012-05-25 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-12-000058.txt Sec File: edgar/data/1487767/0001237899-12-000058-index.htm

2012-05-24 Aberman Michael S (CIK 1487767) through Direct (Vp Strategy And Investor Relat)

Invested in Regeneron Pharmaceuticals Inc bought 500 shares at $24.0 remaining shares owned 10500

Common Stock Regeneron Pharmaceuticals Inc Regn Transaction code: M Exercise or conversion of derivative security


Filed on 2012-05-25 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-12-000058.txt Sec File: edgar/data/1487767/0001237899-12-000058-index.htm

2012-05-24 Aberman Michael S (CIK 1487767) through Direct (Vp Strategy And Investor Relat)

Invested in Regeneron Pharmaceuticals Inc remaining shares owned 287

Common Stock Regeneron Pharmaceuticals Inc Regn


Filed on 2012-05-02 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-12-000051.txt Sec File: edgar/data/1487767/0001237899-12-000051-index.htm

2012-04-30 Aberman Michael S (CIK 1487767) through Direct (Vp Strategy And Investor Relat)

Invested in Regeneron Pharmaceuticals Inc sold 12500.0 shares remaining shares owned 58336

Non-Qualified Stock Option Right To Buy Regeneron Pharmaceuticals Inc Regn exercise price 24.0 has valueitem expiration due date 2020-03-22 underlying security shares 12500.0 underlying security title Common Stock

f1 disposition/acquisition made pursuant to a plan intended to comply with rule 10b5-1(c).
f5 exercisable date, exercise date, exercise price, purchase price, sales price, and/or expiration date is/are not applicable in this case.
f4 the stock option award (combined incentive stock option and non-qualified stock option) vests over five years, commencing one year after the date of grant. 12,500 options vest on the first anniversary, 25,000 options vest on the second anniversary, 25,000 options vest on the third anniversary, 25,000 options vest on the fourth anniversary, and 12,500 options vest on the fifth anniversary of the date of grant.


Filed on 2012-05-02 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-12-000051.txt Sec File: edgar/data/1487767/0001237899-12-000051-index.htm

2012-05-01 Aberman Michael S (CIK 1487767) through Direct (Vp Strategy And Investor Relat)

Invested in Regeneron Pharmaceuticals Inc sold 2300 shares at $135.29 remaining shares owned 10000

Common Stock Regeneron Pharmaceuticals Inc Regn Transaction code: S Open market or private sale of securities

f1 disposition/acquisition made pursuant to a plan intended to comply with rule 10b5-1(c).
f3 represents volume-weighted average price of sales of 2,300 shares of company stock on may 1, 2012 at prices ranging from $135.03 to $135.59. upon request by the commission staff, the company, or a security holder of the company, the reporting person will provide full information regarding the number of shares sold by the reporting person on may 1, 2012 at each separate price.


Filed on 2012-05-02 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-12-000051.txt Sec File: edgar/data/1487767/0001237899-12-000051-index.htm

2012-05-01 Aberman Michael S (CIK 1487767) through Direct (Vp Strategy And Investor Relat)

Invested in Regeneron Pharmaceuticals Inc sold 3862 shares at $134.52 remaining shares owned 12300

Common Stock Regeneron Pharmaceuticals Inc Regn Transaction code: S Open market or private sale of securities

f1 disposition/acquisition made pursuant to a plan intended to comply with rule 10b5-1(c).
f2 represents volume-weighted average price of sales of 3,862 shares of company stock on may 1, 2012 at prices ranging from $134.01 to $134.98. upon request by the commission staff, the company, or a security holder of the company, the reporting person will provide full information regarding the number of shares sold by the reporting person on may 1, 2012 at each separate price.


Filed on 2012-05-02 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-12-000051.txt Sec File: edgar/data/1487767/0001237899-12-000051-index.htm

2012-04-30 Aberman Michael S (CIK 1487767) through Direct (Vp Strategy And Investor Relat)

Invested in Regeneron Pharmaceuticals Inc sold 4170 shares at $138.31 remaining shares owned 16162

Common Stock Regeneron Pharmaceuticals Inc Regn Transaction code: F Payment of exercise price or tax liability by delivering or withholding securities

f1 disposition/acquisition made pursuant to a plan intended to comply with rule 10b5-1(c).


Filed on 2012-05-02 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-12-000051.txt Sec File: edgar/data/1487767/0001237899-12-000051-index.htm

2012-04-30 Aberman Michael S (CIK 1487767) through Direct (Vp Strategy And Investor Relat)

Invested in Regeneron Pharmaceuticals Inc sold 2168 shares at $138.31 remaining shares owned 20332

Common Stock Regeneron Pharmaceuticals Inc Regn Transaction code: F Payment of exercise price or tax liability by delivering or withholding securities

f1 disposition/acquisition made pursuant to a plan intended to comply with rule 10b5-1(c).


Filed on 2012-05-02 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-12-000051.txt Sec File: edgar/data/1487767/0001237899-12-000051-index.htm

2012-04-30 Aberman Michael S (CIK 1487767) through Direct (Vp Strategy And Investor Relat)

Invested in Regeneron Pharmaceuticals Inc bought 12500 shares at $24.0 remaining shares owned 22500

Common Stock Regeneron Pharmaceuticals Inc Regn Transaction code: M Exercise or conversion of derivative security

f1 disposition/acquisition made pursuant to a plan intended to comply with rule 10b5-1(c).


Filed on 2012-05-02 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-12-000051.txt Sec File: edgar/data/1487767/0001237899-12-000051-index.htm

2012-04-30 Aberman Michael S (CIK 1487767) through Direct (Vp Strategy And Investor Relat)

Invested in Regeneron Pharmaceuticals Inc remaining shares owned 287

Common Stock Regeneron Pharmaceuticals Inc Regn


Filed on 2011-12-20 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-11-000075.txt Sec File: edgar/data/1487767/0001237899-11-000075-index.htm

2011-12-16 Aberman Michael S (CIK 1487767) through Direct (Vp Strategy And Investor Relat)

Invested in Regeneron Pharmaceuticals Inc bought 35000 shares remaining shares owned 35000

Non-Qualified Stock Option Right To Buy Regeneron Pharmaceuticals Inc Regn exercise price 52.03 has valueitem expiration due date 2021-12-16 underlying security shares 35000 underlying security title Common Stock

f2 exercisable date, exercise date, exercise price, purchase price, sales price, and/or expiration date is/are not applicable in this case.
f1 the stock option award vests in four equal annual installments, commencing one year after the date of grant.


Filed on 2011-09-07 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-11-000052.txt Sec File: edgar/data/1487767/0001237899-11-000052-index.htm

2011-09-06 Aberman Michael S (CIK 1487767) through Direct (Vp Strategy And Investor Relat)

Invested in Regeneron Pharmaceuticals Inc sold 8334 shares remaining shares owned 70836

Non-Qualified Stock Option Right To Buy Regeneron Pharmaceuticals Inc Regn exercise price 24 has valueitem expiration due date 2020-03-22 underlying security shares 8334 underlying security title Common Stock

f1 disposition/acquisition made pursuant to a plan intended to comply with rule 10b5-1(c).
f7 exercisable date, exercise date, exercise price, purchase price, sales price, and/or expiration date is/are not applicable in this case.
f6 the stock option award (combined incentive stock option and non-qualified stock option) vests over five years, commencing one year after the date of grant. 12,500 options vest on the first anniversary, 25,000 options vest on the second anniversary, 25,000 options vest on the third anniversary, 25,000 options vest on the fourth anniversary, and 12,500 options vest on the fifth anniversary of the date of grant.


Filed on 2011-09-07 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-11-000052.txt Sec File: edgar/data/1487767/0001237899-11-000052-index.htm

2011-09-02 Aberman Michael S (CIK 1487767) through Direct (Vp Strategy And Investor Relat)

Invested in Regeneron Pharmaceuticals Inc sold 4166 shares remaining shares owned 16664

Incentive Stock Option Right To Buy Regeneron Pharmaceuticals Inc Regn exercise price 24 has valueitem expiration due date 2020-03-22 underlying security shares 4166 underlying security title Common Stock

f1 disposition/acquisition made pursuant to a plan intended to comply with rule 10b5-1(c).
f7 exercisable date, exercise date, exercise price, purchase price, sales price, and/or expiration date is/are not applicable in this case.
f6 the stock option award (combined incentive stock option and non-qualified stock option) vests over five years, commencing one year after the date of grant. 12,500 options vest on the first anniversary, 25,000 options vest on the second anniversary, 25,000 options vest on the third anniversary, 25,000 options vest on the fourth anniversary, and 12,500 options vest on the fifth anniversary of the date of grant.


Filed on 2011-09-07 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-11-000052.txt Sec File: edgar/data/1487767/0001237899-11-000052-index.htm

2011-09-07 Aberman Michael S (CIK 1487767) through Direct (Vp Strategy And Investor Relat)

Invested in Regeneron Pharmaceuticals Inc sold 1577 shares at $70.39 remaining shares owned 10000

Common Stock Regeneron Pharmaceuticals Inc Regn Transaction code: S Open market or private sale of securities

f1 disposition/acquisition made pursuant to a plan intended to comply with rule 10b5-1(c).
f5 represents volume-weighted average price of sales of 1,577 shares of company stock on september 7, 2011 at prices ranging from $70.06 to $70.72. upon request by the commission staff, the company, or a security holder of the company, the reporting person will provide full information regarding the number of shares sold by the trust on september 7, 2011 at each separate price.


Filed on 2011-09-07 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-11-000052.txt Sec File: edgar/data/1487767/0001237899-11-000052-index.htm

2011-09-07 Aberman Michael S (CIK 1487767) through Direct (Vp Strategy And Investor Relat)

Invested in Regeneron Pharmaceuticals Inc sold 900 shares at $69.57 remaining shares owned 11577

Common Stock Regeneron Pharmaceuticals Inc Regn Transaction code: S Open market or private sale of securities

f1 disposition/acquisition made pursuant to a plan intended to comply with rule 10b5-1(c).
f4 represents volume-weighted average price of sales of 900 shares of company stock on september 7, 2011 at prices ranging from $69.03 to $69.97. upon request by the commission staff, the company, or a security holder of the company, the reporting person will provide full information regarding the number of shares sold by the trust on september 7, 2011 at each separate price.


Filed on 2011-09-07 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-11-000052.txt Sec File: edgar/data/1487767/0001237899-11-000052-index.htm

2011-09-07 Aberman Michael S (CIK 1487767) through Direct (Vp Strategy And Investor Relat)

Invested in Regeneron Pharmaceuticals Inc sold 700 shares at $68.8 remaining shares owned 12477

Common Stock Regeneron Pharmaceuticals Inc Regn Transaction code: S Open market or private sale of securities

f1 disposition/acquisition made pursuant to a plan intended to comply with rule 10b5-1(c).
f3 represents volume-weighted average price of sales of 700 shares of company stock on september 7, 2011 at prices ranging from $68.59 to $68.96. upon request by the commission staff, the company, or a security holder of the company, the reporting person will provide full information regarding the number of shares sold by the trust on september 7, 2011 at each separate price.


Filed on 2011-09-07 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-11-000052.txt Sec File: edgar/data/1487767/0001237899-11-000052-index.htm

2011-09-07 Aberman Michael S (CIK 1487767) through Direct (Vp Strategy And Investor Relat)

Invested in Regeneron Pharmaceuticals Inc sold 200 shares at $67.39 remaining shares owned 13177

Common Stock Regeneron Pharmaceuticals Inc Regn Transaction code: S Open market or private sale of securities

f1 disposition/acquisition made pursuant to a plan intended to comply with rule 10b5-1(c).
f2 represents volume-weighted average price of sales of 200 shares of company stock on september 7, 2011 at prices ranging from $67.06 to $67.71. upon request by the commission staff, the company, or a security holder of the company, the reporting person will provide full information regarding the number of shares sold by the trust on september 7, 2011 at each separate price.


Filed on 2011-09-07 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-11-000052.txt Sec File: edgar/data/1487767/0001237899-11-000052-index.htm

2011-09-06 Aberman Michael S (CIK 1487767) through Direct (Vp Strategy And Investor Relat)

Invested in Regeneron Pharmaceuticals Inc sold 1916 shares at $65.76 remaining shares owned 13377

Common Stock Regeneron Pharmaceuticals Inc Regn Transaction code: F Payment of exercise price or tax liability by delivering or withholding securities

f1 disposition/acquisition made pursuant to a plan intended to comply with rule 10b5-1(c).


Filed on 2011-09-07 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-11-000052.txt Sec File: edgar/data/1487767/0001237899-11-000052-index.htm

2011-09-06 Aberman Michael S (CIK 1487767) through Direct (Vp Strategy And Investor Relat)

Invested in Regeneron Pharmaceuticals Inc sold 3041 shares at $65.76 remaining shares owned 15293

Common Stock Regeneron Pharmaceuticals Inc Regn Transaction code: F Payment of exercise price or tax liability by delivering or withholding securities

f1 disposition/acquisition made pursuant to a plan intended to comply with rule 10b5-1(c).


Filed on 2011-09-07 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-11-000052.txt Sec File: edgar/data/1487767/0001237899-11-000052-index.htm

2011-09-06 Aberman Michael S (CIK 1487767) through Direct (Vp Strategy And Investor Relat)

Invested in Regeneron Pharmaceuticals Inc bought 8334 shares at $24 remaining shares owned 18334

Common Stock Regeneron Pharmaceuticals Inc Regn Transaction code: M Exercise or conversion of derivative security

f1 disposition/acquisition made pursuant to a plan intended to comply with rule 10b5-1(c).


Filed on 2011-09-07 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-11-000052.txt Sec File: edgar/data/1487767/0001237899-11-000052-index.htm

2011-09-02 Aberman Michael S (CIK 1487767) through Direct (Vp Strategy And Investor Relat)

Invested in Regeneron Pharmaceuticals Inc sold 4166 shares at $64 remaining shares owned 10000

Common Stock Regeneron Pharmaceuticals Inc Regn Transaction code: S Open market or private sale of securities

f1 disposition/acquisition made pursuant to a plan intended to comply with rule 10b5-1(c).


Filed on 2011-09-07 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-11-000052.txt Sec File: edgar/data/1487767/0001237899-11-000052-index.htm

2011-09-02 Aberman Michael S (CIK 1487767) through Direct (Vp Strategy And Investor Relat)

Invested in Regeneron Pharmaceuticals Inc bought 4166 shares at $24 remaining shares owned 14166

Common Stock Regeneron Pharmaceuticals Inc Regn Transaction code: M Exercise or conversion of derivative security

f1 disposition/acquisition made pursuant to a plan intended to comply with rule 10b5-1(c).


Filed on 2011-09-07 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-11-000052.txt Sec File: edgar/data/1487767/0001237899-11-000052-index.htm

2011-09-02 Aberman Michael S (CIK 1487767) through Direct (Vp Strategy And Investor Relat)

Invested in Regeneron Pharmaceuticals Inc remaining shares owned 143

Common Stock Regeneron Pharmaceuticals Inc Regn


Filed on 2010-12-20 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-10-000051.txt Sec File: edgar/data/1487767/0001237899-10-000051-index.htm

2010-12-14 Aberman Michael S (CIK 1487767) through Direct (Vp Strat And Invest Relations)

Invested in Regeneron Pharmaceuticals Inc bought 30000 shares remaining shares owned 30000

Non-Qualified Stock Option Right To Buy Regeneron Pharmaceuticals Inc Regn exercise price 30.63 has valueitem expiration due date 2020-12-14 underlying security shares 30000 underlying security title Common Stock

f2 exercisable date, exercise date, exercise price, purchase price, sales price, and/or expiration date is not applicable in this case.
f1 the stock option award vests in four equal annual installments, commencing one year after the date of grant.


Filed on 2010-03-24 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-10-000020.txt Sec File: edgar/data/1487767/0001237899-10-000020-index.htm

2010-03-22 Aberman Michael S (CIK 1487767) through Direct (Vp Strat And Invest Relations)

Invested in Regeneron Pharmaceuticals Inc bought 79170 shares remaining shares owned 79170

Non-Qualified Stock Option Right To Buy Regeneron Pharmaceuticals Inc Regn exercise price 24 has valueitem expiration due date 2020-03-22 underlying security shares 79170 underlying security title Common Stock

f3 exercisable date, exercise date, exercise price, purchase price, sales price, and/or expiration date is not applicable in this case.
f2 the stock option award (combined incentive stock option and non-qualified stock option) vests over five years, commencing one year after the date of grant. 12,500 options vest on the first anniversary, 25,000 options vest on the second anniversary, 25,000 options vest on the third anniversary, 25,000 options vest on the fourth anniversary, and 12,500 options vest on the fifth anniversary of the date of grant.


Filed on 2010-03-24 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-10-000020.txt Sec File: edgar/data/1487767/0001237899-10-000020-index.htm

2010-03-22 Aberman Michael S (CIK 1487767) through Direct (Vp Strat And Invest Relations)

Invested in Regeneron Pharmaceuticals Inc bought 20830 shares remaining shares owned 20830

Incentive Stock Option Right To Buy Regeneron Pharmaceuticals Inc Regn exercise price 24 has valueitem expiration due date 2020-03-22 underlying security shares 20830 underlying security title Common Stock

f3 exercisable date, exercise date, exercise price, purchase price, sales price, and/or expiration date is not applicable in this case.
f2 the stock option award (combined incentive stock option and non-qualified stock option) vests over five years, commencing one year after the date of grant. 12,500 options vest on the first anniversary, 25,000 options vest on the second anniversary, 25,000 options vest on the third anniversary, 25,000 options vest on the fourth anniversary, and 12,500 options vest on the fifth anniversary of the date of grant.


Filed on 2010-03-24 by Aberman Michael S SEC CIK 1487767 Form 4

Accession 0001237899-10-000020.txt Sec File: edgar/data/1487767/0001237899-10-000020-index.htm

2010-03-22 Aberman Michael S (CIK 1487767) through Direct (Vp Strat And Invest Relations)

Invested in Regeneron Pharmaceuticals Inc bought 10000 shares at $0 remaining shares owned 10000

Common Stock Regeneron Pharmaceuticals Inc Regn Transaction code: A Grant, award, or other acquisition

f1 award of restricted stock under the 2000 long-term incentive plan that vests in its entirety on march 22, 2015.